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Background: The prevalence of adverse drug reactions (ADRs) in hospitalised older patients, their 
clinical presentations, causative drugs, severity, preventability and measurable outcomes are 
unclear, ADRs being an increasing challenge to older patient safety. 
Methods: We systematically searched PubMed, Embase, EBSCO-CINAHL, the Cochrane Library, 
‘grey’ literature and relevant systematic review bibliographies, published from database inception to 
March2020.  We included any study reporting occurrence of in-hospital ADRs as primary or 
secondary outcomes in hospitalised older adults (mean age ≥65 years). Two authors independently 
extracted relevant information and appraised studies for bias. Study characteristics, ADR clinical 
presentations, causative drugs, severity, preventability and clinical outcomes were analysed. Study 
estimates were pooled using random-effects meta-analytic models. 
Results: From 2399 abstracts, we undertook full-text screening in 286, identifying 27 studies (29 
papers). Final analysis yielded a pooled ADR prevalence of 16% (95%CI 12%-22%, I2 98%, 0.8585), in 
a population of 20153 hospitalised patients aged ≥ 65 years of whom 2479 patients experienced ≥1 
ADR. ADR ascertainment was highly heterogeneous. 48.3% of all ADRs involved five presentations: 
fluid/electrolyte disturbances (17.3%), gastrointestinal motility/defaecation disorders (13.3%), renal 
disorders (8.2%), hypotension/blood pressure dysregulation disorders/shock (5.5%) and delirium 
(4.1%). Four drug classes accounted for 57.8% of causative medications i.e. diuretics (19.8%), anti-
bacterials (14.8%), antithrombotic agents (12.2%) and analgesics (10.9%). Pooled analysis of severity 
was not feasible. Four studies reported the majority of ADRs as preventable (55%-95%). 
Conclusion: On average, 16% of hospitalised older patients experience significant ADRs, varying in 
severity and mostly preventable, with commonly prescribed drug classes accounting for most ADRs. 
 




• Adverse drug reactions (ADRs) are highly prevalent in hospitalised older inpatients, with 
commonly prescribed drug classes accounting for the majority ADRs. 
• Cumulatively, twenty ADR presentations represent 90% of all ADRs. 
• Twenty therapeutic drug classes accounted for 94% of all ADRs in older people. 
• There is marked heterogeneity in ADR studies pointing to a need for standardisation of ADR 
ascertainment and assessment.  
• Patient outcomes from ADRs were inadequately and infrequently measured, indicating the need 






The World Health Organisation (WHO) defines an adverse drug reaction (ADR) as “a response to a 
medicine which is noxious and unintended, and which occurs at doses normally used in man”.1 An 
adverse drug event or experience (ADE) is defined as “any untoward medical occurrence that may 
present during treatment with a medicine but which does not necessarily have a causal relationship 
with this treatment”.1 Since 1960, studies have focused on ADR prevalence, with recent emphasis on 
predictive models, associated risk factors, preventability and methods to reduce ADR occurrence. 
Female gender, comorbid complexity and increased number of daily medications are significant risk 
factors for ADRs, particularly in older adults (≥65 years).2 
 ADRs and ADEs represent a significant proportion of older adult acute hospital admissions 
(8.7%3 - 16.6%4) and increase the cost of care by almost one fifth per patient i.e. €2200, more so in 
patients aged over 65.5 Hospital-acquired ADEs prolong length of stay (LOS),5-8 particularly in older 
patients5,8 and greater ADE severity incurs greater hospitalisation costs.9 In hospitalised patients of 
all ages 6-7% will experience serious incident ADRs,10 cognitively impaired older adults being at 
particular risk.11 Preventable ADEs cost almost 50% more than non-preventable ADEs12 and 
importantly tend to occur more frequently in older adults.13,14 Thus, reducing preventable ADRs and 
ADEs in hospitalised older adults could potentially offer substantial economic dividends. 
Several systematic reviews (SRs) have focused on ADRs in hospital,15 yet few deal with ADRs 
in older adults specifically,2,3,11,16,17 or as a subset.4,18,19 Reported ADE/ADR frequency varies widely 
depending on sex, age, time-point ( i.e. at admission versus discharge), study setting (i.e. in-hospital 
versus community-acquired), and specific-disease cohorts. Furthermore, SRs examining older adults 
in isolation report lower ADR frequencies than those reporting older age as a subgroup of all ages.2-
4,18 
Estimates indicate that hospital-acquired ADRs occur frequently, irrespective of age; up to 1 
in 4 hospitalised adults experience ADRs (10.9%10- 23.4%20). Alhawassi et al.2 estimated that 11.5% 
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(95% CI, 0 – 27%)2 of older people experience hospital-acquired ADRs. However, the confidence 
interval for this estimate was wide and the number of studies considered and the overall patient 
population size represented by this estimate are unclear.  
It is evident that ADRs in general occur more frequently in hospital than in other settings and 
that older people are more at risk, yet a dedicated pooled estimate of ADR prevalence in this 
population is lacking. Therefore, the objectives of this systematic review and meta-analysis were: (i) 
to calculate the pooled prevalence of hospital-acquired ADRs in older people (≥65 years), (ii) to 
identify the common clinical presentations of these ADRs, and (iii) to identify associated causative 
medications.  
 
Materials and methods 
This study was registered (PROSPERO CRD42018079095 2018)21 and reported as per PRISMA 
(Preferred Reporting Items For Systematic Reviews And Meta-Analyses)22 and MOOSE (Meta-analysis 
Of Observational Studies in Epidemiology) guidelines23 (Appendix 1). Two investigators conducted 
each step independently, results were compared for agreement, identified discrepancies were 
discussed and consensus reached. 
 
Search Strategy 
PubMed, Embase, Ebsco-CINAHL and Cochrane Library databases were searched from inception until 
March 2020, without language restriction, using terms ‘aged’, ‘adverse drug reaction’, ‘hospitalised’, 
‘multi-morbid’, ‘polypharmacy’ and ‘hospital-acquired’ (Appendix 1-Search terms).  
 
Data extraction  
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Two researchers [EJ, KM] extracted data using a pre-specified template. Authors were contacted for 
further information when insufficient data were reported. Only control arm data were extracted in 
randomised control trials (RCTs).  
 
Eligibility Criteria  
Studies were included if they reported on: 
i) Population: Human participants aged ≥ 65 years. 
ii) Outcome: Proportion of ADRs/ADEs occurring during acute hospitalisation reporting 
methodology for identifying ADRs; details of clinical presentations of ADRs and/or 
causative medications; specifics of severity and/or preventability of ADRs; description of 
ADR assessment methods; evaluation or ADR-related clinical outcomes. 
iii) Design: Any design, with the exception of review publications or case reports 
(bibliographic hand search undertaken). 
In cases of missing or ambiguous data reporting author(s) were contacted seeking clarification. 
 
Assessment of Study Quality 
Included studies were critically appraised using the Cochrane risk of bias tool24 (randomised 
interventional studies) and the modified Newcastle-Ottawa scale (NOS)25 (observational studies).  
 
Statistical Analysis 
i) ADR Prevalence: this was defined as the proportion of participants aged ≥ 65 years 
experiencing ≥ 1 ADR during hospitalisation.  
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ii) ADR clinical presentations: were classified according to the Medical Dictionary for 
Regulatory Activities terminology26 using BioPortal©27,28 reported as the proportion of 
overall number of ADR presentations and validated by sensitivity analysis (Appendix 2). 
iii) Causative drugs: were reported as a proportion of the total count of all reported agents 
using the WHO Anatomical Therapeutic Chemical [ATC] classification system.2931  
All analyses were conducted using the R Language for Statistical Programming.30 Meta-analysis 
models and plots were produced using the Metafor® package.31 For meta-analysis models, 
generalized linear mixed effects model for logit transformed proportions (i.e. metafor::rms.glmm 
(measure = “PLO”)) were used. Forest plots summarise weighted proportions and associated 
confidence intervals (CI).  
 
RESULTS  
Characteristics of identified studies 
Of 2399 retrieved articles, 29 publications involving 27 studies with a combined total of 128580 
patients aged ≥ 65 years met inclusion criteria32-60 (Figure 1).  Publications spanned 6 decades (1965-
2020) and study size varied enormously (97-108548 patients) (Table 1). Only 10 studies reported sex 
for 5704 patients (28.47%) aged ≥ 65 years, of whom 3090 (54%) were female.37,38,40,49,50,54,55,57-60 
 
Quality of studies and risk of bias assessment  
Detailed descriptions of study quality and risk of bias (RoB) are outlined in appendices 3, 4, 5, 6, 7, 8. 
After appraisal, analysis of its impact on pooled estimates (appendix 6) and funnel plot (appendix 8), 
the study by Liao et al.51 was excluded due to concerns regarding the accuracy of their ADR 
proportion estimation methodology (data mining of a hospital ADR reporting system), which was 
inherently prone to underreporting.61 Two studies44,56 of good quality, provided 10065 (49.9%) of 
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patients included in the final analysis, Giardina et al. 44 being 1 of 7 studies (29%) meeting all 
domains of NOS.33,38,39,42,49,58 Onder et al.’s56 description of assessment and evaluation of ADRs was 
deemed inadequate, but it met all other inclusion criteria. ADRs were clearly incident in eleven 
(44%) observational studies (appendix7).  Both included RCTs55,57 had potential bias relating to 
randomisation and blinding (appendix 9). 
 
ADR Prevalence  
The pooled proportion of ADR prevalence by random effects model was 16% (n=20153, 95%CI 12%-
22%, I2 = 98%, 2 0.8585) indicating substantial heterogeneity (Figure 2). Comparison of ADR 
proportions pooled by specialist service setting was just below statistical significance (p=0.051). 
Reporting limitations prevented evaluation by surgical or medical specialty (appendix 10).  
 
 ADR Methodologies 
ADR identification and ascertainment methodologies varied widely between studies, only 4 studies 
(15%)34,39,42,59 described methodologies across all assessment domains (appendix 11 and 16).  Five 
ADR definitions and four causality tools were utilised. The WHO ADR definition and Naranjo ADR 
causality algorithm were concomitantly applied in 8 studies (30%)32,41-43,46,47,53,56 (appendices 11 and 
15). ADR severity was predominantly author-defined in 8 studies (30%).34,38,41,43,45,54-56 Five ADR 
classification methods were described; the Rawlins & Thompson method was solely used for 7 
studies (26%).32,33,39,46,48,50,59 Only 6 studies34,39,42,44,55,59 reported preventable-ADRs, four  
studies39,42,55,59 used Hallas criteria.  
 
Subgroup Analyses  
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 We interrogated heterogeneity via a subgroup meta-analysis of studies recruiting all ages32-34,39,41-
48,52,53 versus solely ≥65 years at baseline.35-38,40,49,50,54-58,60 While still heterogeneous, ADR prevalence 
was higher in this subgroup i.e. 19% (95% CI 13%-27%, I2=98%, 2 0.86, p=0.299) (appendix 12).  
Grouping by ADR definition (appendix 13) did not reduce heterogeneity nor was there a significant 
difference between groups i.e. WHO definition 14%, author-defined 19%, Bates definition 12%, 
Edwards & Aronson definition 17%, local therapeutic committee definition 30%, and undefined in 
23% (p = 0.806).  
Meta-analysis by ADR causality (appendix 14) criteria did not influence prevalence estimation i.e. 
Naranjo criteria 15%, Hallas criteria 12%, Kramer criteria 19%, undefined criteria 15%, WHO-UMC 
22% (p = 0.8094).  
Interrogation by overlapping definition/causality methodologies (appendix 15) did not reduce 
heterogeneity, nor was there a significant difference between definition/causality groups (p=0.383) 
i.e. WHO/WHO-UMC criteria 22%, WHO/Naranjo criteria 10% Edwards & Aronson/Naranjo criteria 
21%. 
 
Reported ADR Presentation 
Nineteen studies (70%)32-39,41-43,45,46,48,50,54-58 reported 2728 ADR presentations in 1886 patients aged ≥ 
65 years. After sensitivity analysis, 3251 ADRs were classified and ranked (appendix 2). Cumulatively, 
twenty clinical presentations represented 90% of all ADRs (Table 2). Details of ADRs by MedDRA-






Nineteen studies34,36-41,43-45,47,49,51,54,55,57-59,3,4 reported medications related to hospital-acquired ADRs, 
by drug name32,39,41-43,45,46,58 or by drug class.32,34-39,41-43,45,46,48,50,51,54,55,57,59 One study only reported 
drugs as causing ADRs when experienced by a pre-defined number of participants.37 One study 
reported grouped ATC drug classes.37,51 Cumulatively, 2428 causative entities were analysed, with 
ATC classification applicable in 2385 cases across 49 therapeutic subgroups. Twenty therapeutic 
subgroups incorporated 94% of all ADRs (Table 3 and appendix 19). The breakdown of causative 
entities by ATC classification is available in appendices 20 and 21. 
The top five anatomical systems affected by ADR-causing drugs were: (i) cardiovascular 
system (769, 32.24%), (ii) central nervous system (415, 17.40%), (iii) anti-infectives for systemic use 
(410, 17.19%), (iv) blood and blood forming organs (329, 13.79%) and (v) alimentary tract and 
metabolism (169, 7.09%). Eleven studies32,34,37-39,41-43,45,46,48 reported ADR-drug relationship; 3 
published, 8 author-provided data, further synthesis was not feasible. 
 
ADR Severity 
Moderate to severe ADR detection ranged from 24% to 100% as reported in eighteen studies.33,34,37-
39,41-43,46,48,50,51,54-59 (appendices 22 and 23).  
 
ADR Preventability 
Seven studies34,39,42,44,46,55,59 reported preventable ADRs; 4 studies had extractable data and used 





Details describing medication-burden were reported in 18 studies.32,38,40,43-51,54-57,59,60 Polypharmacy 
(i.e. a mean/median of ≥ 5 daily medications) was present in 11 studies (appendix 26).32,38,40,43,49,50,54-
57,59,60  In three studies, patients experiencing ADRs had higher numbers of daily medications at 
baseline compared to those who did not.38,56,59 Onder et al. reported that prescription of ≥8 drugs 
daily was strongly associated with ADRs (odds ratio 4.07).56 Giardina et al. studied 4802 patients, 
48% of whom had polypharmacy at baseline; 3646 patients (76%) were aged ≥ 65 years. In this 
cohort, the adjusted odds ratio for in-hospital ADRs was 1.46 (95% CI 1.06-2.03, p<0.05) in patients 
taking ≥4 medications at admission.44 
 
Multi-morbidity 
Baseline multi-morbidity (i.e. a mean/median of ≥ 3 chronic conditions) was reported in 10 
studies.32,38,40,49,51,54,56,59,60 Eleven studies examined co-morbidity as an ADR-associated variable 
(appendix 27).32,38,40,43,46,49,51,54,56,59,60 Three studies reported no significant association between ADR 
risk and degree of multi-morbidity.32,54,59 Corsonello et al. reported higher Cumulative Illness Rating 
Scale scores in the ADR cohort compared to non-ADR cohort i.e. 4.5 versus 3.6 (p<0.05).38 Similarly, 
Onder et al. observed that a significantly higher proportion of older patients with ≥ 4 comorbidities 
experienced ADRs compared to patients with fewer comorbidities.56 Liao et al. observed that 
patients experiencing ADRs had a higher mean Charlson co-morbidity index score than the non-ADR 
cohort (4.06 versus 3.53 p = <0.001.)51  
 
ADR Outcomes 
Clinical outcomes following ADRs were infrequently reported, only 9 papers37,39,43,48,51,54,55,57,59 
commented on mortality and/or LOS. (Appendix 28) Patient groups experiencing hospital-acquired 





This study presents the first meta-analysis of hospital-acquired ADRs in older adults. The principal 
findings are: (i) approximately 1 in 6 older patients experienced an ADR during hospitalisation, (ii) 20 
clinical presentations accounted for 90% of reported ADRs, (iii) 16 routinely prescribed medications 
or medication classes accounted for 90% of all reported ADRs, (iv) ADR detection methodologies 
were highly heterogeneous with resultant large variation in reported prevalence, and (v) tangible 
clinical outcomes following hospital-acquired ADRs are infrequently reported.  
ADR presentations and causative drug agents were explored in isolation given the high level 
of heterogeneity precluding analysis of drug specific ADR associations. However, our findings provide 
focus and some specific targets for future studies of ADR interventions that could benefit older 
patients. For example, the most common ADR presentation was fluid/electrolyte imbalance and the 
most common drug class causing ADRs was diuretics. 
Our estimate of 17.0% of older-patients experiencing ADRs during hospitalisation is 
comparable to Miguel et al. for all ages i.e. 16.9%.62 However, it exceeds previously reported 
estimations of proportions of older patient populations experiencing ADRs during hospitalisation 
(11.5%)2 and contributing to hospitalisation (8.7%4 – 10.7%2,17). Two Italian studies44,56 where ADR 
prevalence estimates were 3%44 and 7%56 provided almost half (49.9%) of patients included in our 
overall analysis, an established pharmacovigilance culture of underreporting of ADRs may account 
for this.63 
 Reported ADR presentations in this study overlap with those described by Laatikainen et al. 
in all ages20 i.e. dizziness, sedation, delirium (neurological events), electrolyte disturbances (renal 
dysfunction), hypo- and hyperglycaemia (endocrine disorders), constipation (GI events) and bleeding 
(haematological events). As Oscanoa et al.3 did not differentiate ADR-presentations leading to 
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hospitalisation in older adults a comparison is not possible. Not surprisingly, these presentations are 
heterogeneous and often non-specific, being easily misinterpreted as new intrinsic geriatric 
conditions by unsuspecting physicians and thereby increasing risk of prescribing cascades.64 
Similar to Wolfe et al.15, Kongkaew et al.18 and Alhawassi et al.2, cardiovascular system 
medications caused most ADRs. Medications affecting the central nervous system had a higher 
propensity for hospital-acquired ADRs compared to those leading to hospitalisation (17.42% versus 
13.8%18), possibly due to differing prescribing patterns and practices between hospital and 
community settings. Equally, patients' recent frailty, change in baseline activities of daily living and 
overall health status from the insult leading to hospitalisation could account for these differences.  
Our study shares six of the top ten drug classes that caused ADR-related hospitalisations in 
older people in the study by Oscanoa et al.3  i.e. antibiotics, oral anticoagulants, digoxin, ACE-
Inhibitors, opioids and oral anti-diabetics.3 NSAIDs and beta-blockers ranked 15th and 21st 
respectively in the present study, compared to 1st and 2nd suggesting that medications causing in-
hospital ADRs differ to those leading to hospitalisation in older adults. Six drug classes i.e. 
antibiotics, anticoagulants, digoxin, diuretics, hypoglycaemic agents and NSAIDs account for two-
thirds of ADRs in all ages 65 Our estimates attribute 54% of hospital-acquired ADRs to the same drug 
classes with different ranking by prevalence. The time interval between studies and our focus being 
entirely on patients aged ≥ 65 years may account for these differences. Our analysis found that 
hospital-acquired ADRs are infrequently caused by NSAIDs i.e. 1.68%. Nevertheless, NSAIDs 
commonly contribute to ADR-related hospitalisations with an overall   higher risk in older patients 
than younger patients (18.8%18, 2.3% - 33%3 versus 7%15 - 11%66).  
Surprisingly, Oscanoa et al.3 did not associate diuretics with ADR-related hospitalisations in 
older patients. Yet, regardless of age, 1 in 6 preventable ADR induced hospitalisations66 and 1 in 10 
of hospital-acquired ADRs are diuretic-related.15 Our estimate of diuretic-related ADR prevalence 
14 
 
was of 19.86% , likely because diuretic prescription is considerably more common in older people 
than in younger age groups. 
Our study found that anti-bacterials were more frequently associated with hospital-acquired 
ADRs in older adults than those of all ages i.e. 14.82% versus 11.0%.15 By comparison, Oscanoa et al. 
reported that antibiotics may have accounted for 1.1% - 22.2% of ADR-associated hospitalisations in 
older adults.3 The availability of newer antibiotics, greater use of broad-spectrum antibiotics and 
evolving resistance patterns may contribute to these differences.  
Irrespective of age, antithrombotic drugs cause more ADR-associated hospitalisations than 
hospital-acquired ADRs i.e. 24%66 versus 12.5%.15 This pattern persists for older patients, where 3.3% 
- 55.6%3 of ADR-related hospitalisations and 12.17% of hospital-acquired ADRs are associated with 
antithrombotic agents. 
Like Gray et al.16, notable heterogeneity existed across our analyses, relating to the variance 
in the studies themselves. Studies spanned several decades, had varying design, heterogeneous 
populations and differing ADR assessment methodologies. Equally, there was global spread of study 
location, such that international differences in health care systems (e.g. licensed medications and 
mandatory national ADR reporting) could contribute to variable results. This heterogeneity is 
significant in itself as it indicates the need for an internationally standardised ADR assessment 
methodology and core outcome set to lessen study variation and ambiguity. Such tools would 
improve future study quality and facilitate meaningful conclusions from multiple studies to support 
improvements in patient outcomes. 
Our study has some limitations, principally examining heterogeneous studies which are 
mostly retrospective and observational and more prone to bias. Wolfe et al.15 reported the highest 
rates of preventable ADRs in prospective observational studies. Thus, there is potential reporting 
bias due to underreporting of some ADRs. Hence, our results may underestimate true ADR 
prevalence in this population. Our study highlights the most frequent ADR presentations and the 
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most frequent causative drugs independently, we could not generate strong recommendations for 
preventing ADRs due to insufficient information of the circumstances of the ADR occurrence. Hence, 
we could not define groupings of “preventable ADR-Drug pairs” which would support targeted 
intervention. Additionally, pooled estimates for clinical outcomes were not feasible given reporting 
limitations. Finally, it is likely that there are missing data relating to identified studies that could not 
be included, as efforts to contact some study authors seeking to obtain missing data were 
unsuccessful. 
Overall, relatively low quality of reporting of patient-centred clinical outcomes was evident 
from our analysis.  Where reported, although not suitable for meta-analysis, patient groups 
experiencing ADRs in-hospital had longer LOS than their non-ADR counterparts. Lack of robust 
outcome reporting prohibits evaluation of these ADRs from a health economic standpoint and 
therefore makes estimation of ADR impact on health-care systems difficult. More concerning is the 
absence of patient-centred ADR-related outcomes such as quality of life. We contend that defining 
ADR incidence and prevalence in specific patient populations is no longer sufficient and that a 
validated reproducible core outcome set for measuring the impact of ADRs on morbidity, quality of 
life, mortality, health resource utilisation and rehospitalisation for older patients and healthcare 
systems is needed.  
Considering the high proportion of older people experiencing clinically significant ADRs 
during hospitalisation, this study confirms the need to predict and prevent ADRs in this high-risk 
patient population. Greater focus on those medications that most frequently cause ADRs leading to 
and occurring during hospitalisation in older people is needed. Routine surveillance of older patients 
prescribed higher risk drug classes represents one way of minimizing ADRs in older patients. Careful 
review of the need for such drugs, consideration of safer alternatives and awareness of the common 
and often non-specific nature of ADR manifestations in older people should, in theory, minimize 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram 





Figure 2. Forrest plot showing proportion of patients aged 65 years or older experiencing an in-hospital ADR. (Liao et al.51 excluded, forest plot illustrating 
inclusion available in appendix 6)
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Table 1. Summary of characteristics of the 29 papers (27 studies) included in systematic review. 
Source Country Language  Design Hospital / Ward Setting Population Duration 
(months) 






Ayub32 Brazil English Pro ICU Adults 6 270 97 57.3 ± 16.3c 57 
Bowman33 U.S.A. English Post-H GIM & ICU Adults 4 1024 301 54 ± 18 c - 
Caldron-Ospina34  Colombia English Pro UH, ward setting not described Adults 1 104 48 - 54 
Cheong35,36 Singapore English Retro TH, geriatric wards Older adults 1 150 150 89.7 ± 4.0 c -  
Conforti37 Italy English Pro UH, geriatric wards ≥ 65 yrs with ADRs§ 6 1023 1023 81.9 ± 7.1 c 49 
Corsonello38 Italy English Pro Collaborative group, medical ≥ 65 yrs 3 506 506 80.1 ± 6 c 46 
Davies39 U.K. English Pro UH, medical and surgical wards Adults 6 3322 1787 - - 
Fernandez-Regueiro40  Spain Spanish Pro Internal medical service ≥ 65 yrs ≥ 1 PIM <48o 5 97 97 81.3 ± 6.6 c 45 
Ganeva41 Bulgaria English Pro UH, acute dermatology service Adults  24 1041 244 48.9 ± 18.9 c 42 
Ganeva43 Bulgaria English Pro UH, acute dermatology service Adults 18 674 203 - 47 
Ganeva42 Bulgaria English Pro UH, acute dermatology service Adults 60 750 222 - - 
Giardina44 Italy English Pro 2 hospitals, 6 wards◊  Adults  24 4802 3646 - - 
Gonzalez-Martin45  Chile Spanish Pro UH, internal medicine Adults  ≥ 65 yrs ¥ 8 201 106 - 47 
Hailu46  Ethiopia  English Pro UH, medical and surgical wards ≥ 60 yrs 4 200 121 67.3 ± 7.3 c 67.5 
Harugeri47 India English Pro TH, medical wards In-patient, ≥ 60 yrs 18 920 370 - 59 
Kaur48  India English Pro TH, geriatric wards Adults > 50 yrs 21 658 467 - 59 
Lavan49  Ireland English Pro SENATOR 6 European trial sites ≥65 yrs multi-morbid ≤72o  18 644 644 77.8 ± 7.4 c 48 
Leach50  U.K. English Pro District hospital, geriatric unit Consecutive admissions 5 500 500 78.3c 46 
Liao51 Taiwan English Retro ADR reporting system analysis Older inpatients 72 108548 108548 - - 
Mohebbi52  Iran English Pro 2 CCU wards Adults, ≥ 1 CVS drug 8 677 204 - 65 
Mugosa53  Montenegro English Pro Critical care, cardiology centre Adults ≥ 72o 6 200 64 60.5 ± 10 c 69 
O’Connor54 Ireland English Pro UH, medical & surgical ED admissions ≥ 65yrs† 12 513 513 77 (72-82)d 44 
O’Connor55 Ireland English RCT UH, medical & surgical Admissions ≥ 65 yrs† 4 372 372 78 (72-84)d 50 
Onder56  Italy English Pro 83 centres, 4 European sites  ≥ 65 yrs hospitalised 19** 6419 6419 78 ± 7.9 c - 
O’Sullivan57  Ireland English RCT UH, medical & surgical  Admissions ≥ 65 yrs 13 376 376 78 (72-84) d 51 
Reichel58 U.S.A. English Pro County general hospital Admissions ≥ 65 yrs 8 500 500 77.9c 43 
Tangiisuran59  U.K. English Pro UHs, 4 care of elderly wards ≥ 80 yrs*** 6 560*** 560*** 87 ± 5.6 c 37 
Tangiisuran60 U.K. 
 










Legend: yrs – years; M – Male; Pro – prospective observational; ICU – Intensive care unit;  c – mean ± standard deviation; Post-H – Post-hoc analysis;  GIM – general internal medicine; UH – 
University Hospital; Retro – retrospective observational; TH – Tertiary Hospital; ADRs – adverse drug reactions; § - ADRs at presentation and in-hospital; PIM – Potentially inappropriate 
medication; o – hours since admission; ◊ - GIM, geriatrics, metabolic diseases; ¥ - excluded physical and cognitive impairment; SENATOR - Software ENgine for the Assessment & optimization 
of drug and non-drug Therapy in Older peRsons; CCU – coronary care unit; CVS – cardiovascular system; ED – Emergency department; † – excluded ICU, palliative, clinical pharmacology, 
psychiatry, geriatric medicine; d – median (Interquartile range);  RCT – randomised control trial; ** combined duration over (1988, 1991, 1993, 1995, 1997); ***subset of population described 
in 2014 paper; D – development cohort, v – validation cohort. 
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Table 2. Most frequently reported ADR presentations. 
Rank MedDRA-SOC® ADR Classification n % Of 
(3251) 
ADR Presentation Details† 
1 Electrolyte and fluid balance conditions  561 17.26% Potassium imbalance 325 (9.99%) – hypokalaemia 275 (8.46%), hyperkalaemia 50 (1.54%) 
Sodium imbalance 29 (0.89%) – hyponatraemia 27 (0.83%), hypernatraemia 2 (0.06%) 
Fluid volume 5 (0.15%) – increased 3 (0.09%), decreased 2 (0.06%) 
2 Gastrointestinal motility and defaecation 
conditions  
480 14.76% Constipation 334 (10.27%) 
Diarrhoea 146 (4.49%) 
3 Renal disorders (excl. nephropathies)  267 8.21% Acute kidney injury 265 (8.15%) 
Renal failure complications 2 (0.06%) 
4 Decreased and nonspecific blood 
pressure disorders and shock  
179 5.51% Vascular hypotensive disorders 179 (5.51%) – postural hypotension 98 (3.02%), hypotension 81 (2.49%) 
5 Delirium (incl. confusion)  132 4.06% Confusion 132 (4.06%) 
6 Injuries NEC 123 3.78% Fall 123 (7.8%) 
7 Cardiac rate and rhythm disorders 122 3.75% Bradycardia 102 (3.14%), AV Block 12 (0.37%), tachycardia 8 (0.24%) 
8 Unspecified / unclassifiable 
cardiovascular disorders* 
110 3.38% Cardiovascular complications* 97 (2.98%) 
“Cardiovascular System”* 13 (0.40%) 
9 Haematology investigations – deranged 
coagulation and bleeding analyses  
98 3.01% INR increase 97 (2.98%) 
Low prothrombin time 1 (0.03%) 
10 Unspecified / unclassifiable 
gastrointestinal disorders* 
90 2.77% “Gastrointestinal”* 90 (2.77%) 
11 Vascular haemorrhagic disorders 89 2.74% Haemorrhages NEC 89 (2.74%) – Bleeding 69 (2.13%), haematoma 20 (0.62%) 
12 Gastrointestinal haemorrhages NEC 85 2.61% Gastrointestinal bleeding 85 (2.61%) 
13 Unspecified / unclassifiable nervous 
system disorders* 
80 2.46% “Neurologic”* 68 (2.09%)  
“Central nervous system”* 12 (0.37%) 
14 Glucose metabolism disorders (incl. 
diabetes mellitus)  
74 2.28% Hypoglycaemia 51 (1.57%) 
Hyperglycaemia 23 (0.71%) 
15 Epidermal and dermal conditions 72 2.21% Rashes, eruptions and exanthems NEC 72 (2.21%) 
16 Gastrointestinal signs and symptoms  71 2.18%  Nausea/vomiting 68 (2.09%), dyspepsia 2 (0.06%), abdominal pain 1 (0.03%) 
17 Grouped unspecified / unclassifiable 
neuropsychiatric disorders* 
68 2.09%  “Neuropsychiatric”* 68 (2.09%) 
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18 Fungal infectious disorders - candida 
infections  
67 2.06%  Thrush 67 (2.06%) 
19 Neurological disorders NEC 63 1.94%  Disturbances in consciousness NEC 63 (1.94%) 
20 Allergic conditions 54 1.66%  Allergy 54 (1.66%) 
†reporting most common presentation per MedDRA-SOC® description, further details of subgroup / breakdown available in appendix 18. Breakdown of ADR 
presentations by ADR detail.  




Table 3. Most frequently reported ADR culprit drugs. 
Rank ATC 2nd Level Therapeutic Subgroup n % (2385) Most Frequently Reported Pharmacological Subgroup* –chemical subgroup** (drug name/chemical 
substance***) 
1 Diuretics 473 19.83% High ceiling diuretics 234 (9.81%) – sulfonamides 232 (9.73%) (furosemide 194), (bumetanide 32) 
Potassium sparing 47 (1.97%) 
Low ceiling diuretics 27 (1.13%) – thiazides 24 (1.01%), excl. thiazides 13 (0.55%) 
Combinations 5 (0.21%) 
2 Antibacterials for systemic use 354 14.84% Beta-lactams penicillins 106 (4.44%) 
Cephalosporins 54 (2.26%) 
Macrolides, lincosamides and streptogramins 46 (1.93%) – macrolides 43 (1.80%) 
Quinolones 29 (1.22%) – fluoroquinolones 29 (1.22%) 
Imidazole derivatives, glycopeptides, polymixins 26 (1.09%) (metronidazole 16) 
Sulfonamides and trimethoprim 23 (0.96%) 
Aminoglycosides 6 (0.25%) 
Tetracyclines 1 (0.04%) 
3 Antithrombotic agents 292 12.24% Vitamin K antagonists 82 (3.44%) 
Heparin group 84 (3.52%) 
Platelet aggregation inhibitors 77 (3.23%) 
Enzymes 3 (0.13%) 
4 Analgesics 260 10.90% Opioids 205 (8.60%) – natural opium alkaloids 44 (1.84%) (Morphine 40), tramadol 28 (1.17%), 
phenylpiperidine derivatives 6 (0.25%), combination with non-opioid analgesics 4 (0.17%) 
Other analgesics and antipyretics 55 (2.31%) – anilides 34 (1.43%) (co-codamol 31) 
5 Drugs for obstructive airway diseases 
(OAD) 
113 4.74% Adrenergics, inhalants 78 (3.27%) – beta-2-adrenoceptor agonists 62 (salbutamol 60) 
Other drugs used for OAD 23 – xanthines 23 (theophylline 12) 
6 Agents acting on the renin-angiotensin 
system 
98 4.11% ACE inhibitors, plain 39 (1.63%) – (Ramipril 14) 
Angiotensin II receptor blockers (ARBs), plain 12 (0.50%)      
7 Psycholeptics 92 3.86% Anxiolytics 61 (2.56%)– benzodiazepine derivatives 60 
Antipsychotics 18 (0.76%) 
Hypnotics and sedatives 13 (0.55%)  
8 Corticosteroids for systemic use 77 3.23% Glucocorticoids 60 (2.52%) – (prednisolone 41) 
9 Cardiac therapy 71 2.98% Cardiac glycosides 44 (1.85%) – (digoxin 39) 
Vasodilators used in cardiac diseases 12 (0.50%) 
Antiarrhythmics, class I and III 10 (0.42%) – (Amiodarone 10) 




Blood glucose lowering drugs excl. insulin 20 (0.84%) 
11 Antimycobacterials 54 2.26% Drugs for treatment of tuberculosis 54 (2.26%) 
12 Antihypertensives 52 2.18% Not specified by paper 52 (2.18%) 
13 Mineral supplements 50 2.10% Calcium 41 (1.72%) 
Potassium 9 (0.38%) 
14 Calcium channel blockers 41 1.72% Not specified by paper 30 (1.26%) 
Selective with direct cardiac effects 7 (0.29%) 
Selective with mainly vascular effects 4 (0.17%) 
15 Anti-inflammatory and antirheumatic 
products 
40 1.68% Antiinflammatory and antirheumatic products, non-steroids 40 (1.68%) 
16 Antiepileptics 30 1.26% Barbituates and derivatives 18 (0.76%) – (phenobarbital 18)  
Carboxamide derivatives 9 (0.38%) 
17 Drugs for acid related disorders 26 1.09% Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 26 (1.09%) 
18 Drugs for constipation 24 1.01% Drugs for constipation 10 (0.42%) – (Enemas 10) 
19 Anti-anaemic preparations 22 0.92% Iron preparations 20 (0.84%) – (ferrous sulphate 16) 
Vitamin B12 and folic acid 1 
20 Psychoanaleptics 20 0.84% Anti-depressants 19 (0.80%) – (selective serotonin reuptake inhibitors 10) 
Anti-dementia drugs 1 (0.04%) 
 
* - ATC 3rd level, ** - ATC 4th level, *** - ATC 5th level (only reported when n ≥10). Additional information / level breakdown available in appendix 22 
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A trained biomedical academic librarian assisted with the search strategy design. Two clinically 
trained investigators (EJ as a senior resident in geriatric medicine and KM as a pharmacist with 
expertise in geriatric pharmacotherapy) screened papers identified from the search for inclusion, 
firstly by title and abstract, and then full-text screening of shortlisted papers. 
PubMed 
old* OR aged OR ageing OR aging OR elderly OR geriatric* OR "Aged"[Mesh] OR "Aged, 80 and over"[Majr] OR 
"Aged, 80 and over"[Mesh] 
AND 
Adverse drug effect OR Adverse drug effects OR Adverse drug event OR Adverse drug events OR Adverse drug 
reaction OR Adverse drug reactions OR Drug induced disease OR Drug induced diseases OR Drug induced 
morbidity OR Drug induced injury Drug related morbidity OR Drug related problem OR Drug related problems 
OR Medication error OR Medication errors OR Medication related problem OR Medication related injury OR 
Medication related disease OR Medication related toxicity OR Toxicity OR Adverse event OR adverse reaction 
OR drug reaction OR drug event OR adverse outcome OR adverse drug outcome OR adverse drug outcomes OR 
adverse medication outcome OR adverse medication outcomes OR Side effect OR unintended effect OR 
unintended effects OR Unintended reaction OR Unintended reactions OR Unintended outcome OR Unintended 
outcomes OR Unintended event OR Unintended events OR Unintended morbidity OR Unintended problem OR 
Unintended injury OR Adverse drug OR "Drug-Related Side Effects and Adverse Reactions"[Mesh] 
AND 
admis* OR admit* OR inpatient OR in-patient OR ward OR Ward-based OR hospitali* OR Hospital OR In 
hospital OR In-hospital OR "Inpatients"[Mesh] 
AND 
Multimorbid OR Multi-morbid OR Multimorbidity OR Multi-morbidity OR Multimorbid* OR Comorbid OR co-
morbid OR morbid* OR co-morbid* OR "Comorbidity"[Majr] OR "Comorbidity"[Mesh] 
AND 
Polypharmacy OR drug combinations OR multiple drugs OR multiple medications OR multiple medication OR 
multiple medicines OR "Polypharmacy"[Mesh] 
AND 
Nosocomial OR Iatrogenic OR Hospital-acquired OR Hospital acquired OR Post-admission OR Post admission 
OR During admission OR During-admission OR Avoidable OR Avoided OR Avoid* OR Preventable OR prevented 
OR Prevent* OR "Iatrogenic Disease"[Mesh] OR "Secondary Prevention"[Mesh] 
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old OR aged OR ageing OR aging OR elderly OR geriatric OR 'aged'/exp OR Old* 
AND 
adverse AND ('drug'/exp OR drug) AND effect OR adverse AND drug AND effects OR adverse AND drug AND 
event OR adverse AND drug AND events OR adverse AND drug AND reaction OR adverse AND drug AND 
reactions OR drug AND induced AND disease OR drug AND induced AND diseases OR drug AND induced AND 
morbidity OR drug AND induced AND injury OR drug AND related AND morbidity  OR drug AND related AND 
problem OR drug AND related AND problems OR medication AND error OR medication AND errors OR 
'medication'/exp OR medication) AND related AND problem OR medication AND related AND injury OR 
medication AND related AND disease OR medication AND related AND toxicity OR Toxicity  OR adverse AND 
event OR adverse AND reaction OR drug AND reaction OR drug AND event OR adverse AND outcome OR 
adverse AND drug AND outcome OR adverse AND drug AND outcomes OR adverse AND medication AND 
outcome OR adverse AND medication AND outcomes OR side AND effect OR unintended AND effect OR 
unintended AND effects OR unintended AND reaction OR unintended AND reactions OR unintended AND 
outcome OR unintended AND outcomes OR unintended AND event OR unintended AND events OR unintended 
AND morbidity OR unintended AND problem OR unintended AND injury OR adverse AND drug OR 'adverse 
event'/exp OR 'adverse drug reaction'/exp 
AND 
admis* OR admit* OR inpatient OR “In patient” OR Ward OR 'ward based' OR hospitali* OR Hospital OR In 
hospital OR 'in hospital' OR inpatient* OR 'hospital patient'/exp 
AND 
Multimorbid OR 'multi morbid' OR Multimorbidity OR 'multi morbidity' OR Multimorbid* OR Comorbid OR 'co 
morbid' OR morbid* OR 'co morbid*' OR 'multiple chronic conditions'/exp OR 'comorbidity'/exp 
AND 
Polypharmacy OR drug AND combinations OR multiple AND drugs OR multiple AND medications OR multiple 
AND medication OR multiple AND medicines OR 'polypharmacy'/exp 
AND 
Nosocomial OR Iatrogenic OR 'hospital acquired' OR hospital AND acquired OR 'post admission' OR post AND 
admission OR during AND admission OR 'during admission' OR Avoidable OR Avoided OR Avoid* OR 
Preventable OR prevented OR Prevent* OR 'iatrogenic disease'/exp OR 'secondary prevention'/exp 
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old* OR aged OR ageing OR aging OR elderly OR geriatric* OR (MH "Aged+") 
AND 
Adverse drug effect OR Adverse drug effects OR Adverse drug event OR Adverse drug events OR Adverse drug 
reaction OR Adverse drug reactions OR Drug induced disease OR Drug induced diseases OR Drug induced 
morbidity OR Drug induced injury OR Drug related morbidity OR Drug related problem OR Drug related 
problems OR Medication error OR Medication errors OR Medication related problem OR Medication related 
injury OR Medication related disease OR Medication related toxicity OR Toxicity OR Adverse event OR adverse 
reaction OR drug reaction OR drug event OR adverse outcome OR adverse drug outcome OR adverse drug 
outcomes OR adverse medication outcome OR adverse medication outcomes OR Side effect OR unintended 
effect OR unintended effects OR Unintended reaction OR Unintended reactions OR Unintended outcome OR 
Unintended outcomes OR Unintended event OR Unintended events OR Unintended morbidity OR Unintended 
problem OR Unintended injury OR Adverse drug OR (MH "Adverse Drug Event+") 
AND 
admis* OR admit* OR inpatient OR in-patient OR ward OR Ward-based OR Ward based OR hospitali* OR 
Hospital OR In hospital OR In-hospital OR (MH "Inpatients") OR (MH "Aged, Hospitalized") 
AND 
Multimorbid OR Multi-morbid OR Multimorbidity OR Multi-morbidity OR Multimorbid* OR Comorbid OR co-
morbid OR morbid* OR co-morbid* OR comorbid* OR  (MH "Comorbidity") 
AND 
Polypharmacy OR drug combinations OR multiple drugs OR multiple medications OR multiple medication OR 
multiple medicines OR (MH "Polypharmacy") 
AND 
Nosocomial OR Iatrogenic OR Hospital-acquired OR Hospital acquired OR Post-admission OR Post admission 
OR During admission OR During-admission OR Avoidable OR Avoided OR Avoid* OR Preventable OR prevented 
OR Prevent* OR (MH "Iatrogenic Disease") OR (MH "Preventive Health Care+") 
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Study Eligibility Criteria  
Studies that examined or as a subset reported on hospital-acquired ADRs/ADEs were included. If 
ADR data could not be extracted or ambiguity existed regarding methodologies the author(s) were 
contacted for further clarification.  
Studies were included if they reported on (a) human participants aged ≥ 65 years, (b) ADR 
occurrence during acute hospitalization, and (c) the methodology used to identify the occurrence of 
an ADR. 
Studies were excluded if (i) all participants were under 65 years, (ii) ADRs occurred in outpatient, 
community or primary care settings, (iii) the setting of ADR occurrence was unclear, (iv) they 
described a single drug or particular ADR presentation in isolation (as not representative of our 
cohort), (v) they were review publications or case reports (bibliographic hand search undertaken), 
(vi) they related to medication errors (included if reported ADR subset), (vii) they related to 




All analysis were conducted using the R Language for Statistical Programming.1 Meta-analysis models 
and plots were produced using the Metafor® package.2 For meta-analysis models we used a 
generalized linear mixed effects model for logit transformed proportions (i.e. 
metafor::rms.glmm(measure = “PLO”)). 
ADR Prevalence  
ADR prevalence was defined as the proportion of participants aged ≥ 65 years experiencing ≥ 
1 ADR during hospitalisation. Prevalence was chosen over incidence as details pertaining to the 
duration of each hospital admission was poorly reported in included studies i.e. prevalence is the 
proportion of cases in the population at a given time rather than rate of occurrence of new cases. As 
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the admission durations were not comparable or standardised across studies (duration of 
hospitalisations poorly reported) we chose point prevalence as the most appropriate 
epidemiological measure to represent pooled proportions. Pooled prevalence estimates were 
calculated using the random-effects meta-analytic model implying that studies come from different 
populations i.e. there is no one single “true” estimate. Forest plots summarise weighted proportions 
and associated 95% CIs.  
Culprit Drugs 
Causative drugs were classified according to the WHO Anatomical Therapeutic Chemical 
[ATC] coding system.3 When more than one drug was accountable per ADR, each drug was counted 
individually. Therapeutic subgroups were reported as a proportion of the total count of all reported 
causative drugs. This strategy allows for comparison across studies given the lack of a common 
reporting system between studies.   
ADR Presentation 
ADR clinical presentations were classified according to the Medical Dictionary for Regulatory 
Activities (MedDRA) terminology4 using BioPortal©.5,6 When studies grouped ADRs involving multiple 
MedDRA®4 subgroups, equal weighting was applied to each subgroup and validated by sensitivity 
analysis to results when grouped ADRs were excluded (see eSupplement-eTable 2). 
The absolute number of ADR presentations was indeterminable as some studies only 
reported ADRs when a predetermined threshold was met. Proportions of ADR presentations were 
calculated with the number of ADRs specific to the individual presentation as the numerator and 
overall number of reported ADR presentations as the denominator. 
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Electrolyte and fluid balance 
conditions  
461 19.78% 19.78% 561 17.26% 17.26% 
2 2 
Gastrointestinal motility and 
defaecation conditions  
392 16.82% 36.59% 432 13.29% 30.54% 
3 3 
Renal disorders (excl. 
nephropathies)  
150 6.44% 43.03% 267 8.21% 38.76% 
4 4 
Decreased and nonspecific 
blood pressure disorders and 
shock  
126 5.41% 48.43% 179 5.51% 44.26% 
15 5 Deliria (incl. confusion)  52 2.23% 50.66% 132 4.06% 48.32% 
16 6 Injuries NEC 34 1.46% 52.12% 123 3.78% 52.11% 
10 7 Rate and rhythm disorders 74 3.17% 55.30% 122 3.75% 55.86% 
11 8 
Epidermal and dermal 
conditions 
72 1.07% 59.46% 118 3.63% 59.49% 
19 9 Neurological disorders NEC 25 4.72% 64.18% 111 3.41% 62.90% 
5 10 
Unspecified / Unclassifiable 
Cardiovascular 
110 4.20% 68.38% 110 3.38% 66.29% 
6 11 
Haematology investigations - 
Coagulation and bleeding 
analyses  
98 3.86% 72.24% 98 3.01% 69.30% 
7 12 
Unspecified / unclassifiable 
Gastrointestinal disorders 
90 3.82% 76.06% 90 2.77% 72.07% 




67 0.47% 79.41% 85 2.61% 77.42% 
26 15 
unspecified / unclassifiable 
nervous system disorders 
11 3.17% 82.58% 80 2.46% 79.88% 
9 16 
Glucose metabolism disorders 
(incl. diabetes mellitus)  
74 2.62% 85.20% 74 2.28% 82.16% 
14 17 
Gastrointestinal signs and 
symptoms  
61 0.00% 85.20% 71 2.18% 84.34% 
63 18 
Unspecified / unclassifiable 
neuropsychiatric disorder 
0 2.87% 88.07% 68 2.09% 86.43% 
12 19 
Fungal infections disorders - 
Candida infections  
67 0.34% 88.42% 67 2.06% 88.50% 
29 20 Allergic conditions 8 1.16% 89.58% 54 1.66% 90.16% 
17 21 
Anaemias nonhaemolytic and 
marrow depression 
27 1.12% 90.69% 27 0.83% 90.99% 
18 22 
Unspecifed / unclassifiable - 
Metabolism and nutrition 
disorders 
26 5.41% 48.43% 26 0.80% 91.79% 
65 23 "Other" 0 0.00% 90.69% 23 0.71% 92.49% 
20 24 
Urinary tract signs and 
symptoms 
22 0.94% 91.63% 22 0.68% 93.17% 
21 25 Respiratory disorders NEC  20 0.86% 92.49% 20 0.62% 93.79% 
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Bacterial infectious disorders - 
Clostridia infections  




7 0.69% 94.29% 17 0.52% 94.89% 
23 28 
Hepatobiliary investigations - 
liver function analyses 
16 0.69% 94.98% 16 0.49% 95.39% 
24 29 Platelet disorders  16 0.64% 95.62% 16 0.49% 95.88% 
25 30 
Unspecified / Unclassifiable 
Blood and lymphatic system 
disorders 
15 0.43% 96.05% 16 0.49% 96.37% 
27 31 
Gastrointestinal stenosis and 
obstruction  
10 0.39% 96.44% 10 0.31% 96.68% 
28 32 Headaches 9 0.34% 96.78% 9 0.28% 96.95% 
30 33 
Joint disorders - Crystal 
arthropathic disorders  
8 0.34% 97.13% 8 0.25% 97.20% 
31 34 Toxicity to various agents  8 0.26% 97.38% 8 0.25% 97.45% 
33 35 
Disturbances in thinking and 
perception  
6 0.13% 97.51% 6 0.18% 97.63% 
39 36 
Movement disorders (incl 
parkinsonism)  
3 0.00% 97.51% 6 0.18% 97.82% 
62 37 
Cognitive and attention 
disorders and disturbances NEC 
0 0.21% 97.73% 6 0.18% 98.00% 
34 38 
Neurological signs and 
symptoms NEC 
5 0.21% 97.94% 5 0.15% 98.15% 
35 39 
Unspecified / unclassifiable 
Hepatobiliary disorders 
5 0.13% 98.07% 5 0.15% 98.31% 
36 40 Body temperature conditions  3 0.13% 98.20% 4 0.12% 98.43% 
42 41 
unspecified / unclassifiable 
respiratory system  
3 0.00% 90.69% 4 0.12% 98.55% 
37 42 
Bone disorders (excl. congenital 
and fractures) - metabolic bone 
disorders 
3 0.13% 98.33% 3 0.09% 98.65% 
38 43 
Bone, calcium, magnesium and 
phosphorus metabolism 
disorders  
3 0.13% 98.46% 3 0.09% 98.74% 
40 44 Nephropathies  3 0.13% 98.71% 3 0.09% 98.92% 
41 45 
Procedural related injuries and 
complications NEC - Cardiac and 
vascular procedural 
complications 
3 0.13% 98.84% 3 0.09% 99.02% 
43 46 White blood cell disorders 3 0.00% 98.84% 3 0.09% 99.11% 
64 47 Missing 0 0.09% 98.93% 3 0.06% 99.17% 
44 48 
Anterior eye structural change, 
deposit and degeneration 
2 0.09% 99.01% 2 0.06% 99.23% 
45 49 Bone and joint injuries  2 0.09% 99.10% 2 0.06% 99.29% 
46 50 Cardiac failure 2 0.09% 99.18% 2 0.06% 99.35% 
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Glaucoma and ocular 
hypertension  
2 0.04% 99.31% 2 0.06% 99.48% 
56 53 Muscle disorders 1 0.09% 99.40% 2 0.06% 99.54% 
49 54 Oral soft tissue conditions  2 0.09% 99.49% 2 0.06% 99.60% 
50 55 Seizures (incl. subtypes)  2 0.09% 99.57% 2 0.06% 99.66% 
51 56 
Toxicology and therapeutic drug 
monitoring - antibiotic level 
2 0.04% 99.61% 2 0.03% 99.69% 
52 57 Asthenic conditions  1 0.04% 99.66% 1 0.03% 99.72% 
53 58 Chest pain 1 0.04% 99.70% 1 0.03% 99.75% 
54 59 Gait disturbances  1 0.04% 99.74% 1 0.03% 99.78% 
55 60 Inflammations 1 0.04% 99.79% 1 0.03% 99.82% 
57 61 
Purine and pyrimidine 
metabolism disorders  
1 0.04% 99.83% 1 0.03% 99.85% 
58 62 
Therapeutic and nontherapeutic 
effects (excl. toxicity)  
1 0.04% 99.87% 1 0.03% 99.88% 
59 63 Vascular hypertensive disorders  1 0.13% 98.33% 1 0.09% 98.65% 
60 64 
Viral infectious disorders - 
herpes viral infections 
1 0.04% 99.91% 1 0.03% 99.91% 
61 65 Failure 0 0.00% 99.91% 1 0.03% 99.94% 
61 66 
Exposures, chemical injuries and 
poisoning 
1 0.04% 99.96% 1 0.03% 99.97% 
62 67 




1 0.03% 100.00% 
   2385* 
100.00
%  3251 100.00%  
Sens. – sensitivity, Class. – classifiable by MedDRA-SOC®, cumul. – Cumulative count, excl. – excluding, Incl. – 
including, NEC – not elsewhere classified. 
*2728 ADR presentations reported in nineteen papers,7-26 397 reported by papers were not classifiable by 
MedDRA-SOC® classification, resulting in 2385 ADRs being accounted for in “classifiable” count. Sensitivity 
analysis applied equal weighting to all presentations in “grouped” reporting therefore overall 3251 
presentations accounted for in sensitivity analysis count.  
Green shading represents direct agreement between MedDRA-SOC® classifiable and sensitivity analysis by 
ranking. Yellow highlights presentation falls in top 10 ranking in either classifiable or sensitivity rankings, and 
red highlights top 15 in either classifiable of sensitivity rankings. The top 15 in both cases were highlighted 
within top 20 across two ranking systems. 
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Risk of Bias (RoB) and Quality Assessment 
Appendix 3. Descriptive summary of RoB / Quality justification and judgements of 
domains of NOS of included observational Studies (provided in alphabetical order) 
Ayub 2009, Bowman 1996  














of the exposed 
cohort 
1 
Description of population, 
setting, duration of study, 
selection of participants and 
sample size calculation.  
1 
Description of population, 
setting and duration of study 
and selection of participants.  




Description of population, 
setting, duration of study and 
sample size calculation. 
1 
Description of population, 
setting and duration of study 




Description of patient/episode 
review; personnel conducting 
review, timing of review, data 





personnel conducting review, 
timing of review and data 
sources used. 
Demonstration 
that outcome of 
interest was not 
present at start of 
study 
0 
Inadequate - no mention of 
assessment of ADRs prior to 
admission.  
1 
Description of review for ADR 
at admission. 
E1 - Assessment of 
outcome  
1 
Description of ADR identification, 
collection of pertaining details, 
and use of Naranjo algorithm to 
assess.  
1 
Description of ADR 
identification, collection of 
pertaining details, and 
evaluation. 
E2 - Was follow-up 
(FUP) long enough 
for outcomes to 
occur  
1 
Description of FUP from 
admission until discharge / 
deceased (Intensive Care Unit) 
1 
Description of FUP from 
admission, throughout 
hospital stay until discharge.  
E3 - Adequacy of 
follow up of 
cohorts 
1 
All patients followed for duration 
of ICU admission 
Missing data - some outcome 
data missing but accounted for 
by author 
1 
Patients adequately followed. 
No evidence of loss to FUP 
during hospitalisation (i.e. 
missing data) 
 

















of the exposed 
cohort 
1 
Description of population, 
setting, selection of participants 
and sample size calculation. 
? 
Inadequate – unclear as to 
how 150 participants were 
selected.  
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, selection of participants 
and sample size calculation. 
? 
Inadequate – unclear as to 
how 150 participants were 
selected.  
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 
0 
Inadequate -  Unable to 
determine method of 
attainment of exposure 
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Choeng 10,11  
2018 
Justification 
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
1 
Description of exclusion of 
patients hospitalized because of 
an ADR. 
0 
Inadequate - no mention of 
assessment of ADRs prior to 
admission. 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, and 
independent evaluation (WHO 
causality). 
? 
Inadequate – unclear as to 
the source and method of 
assessment of outcome. 
E2 - Was follow-up 
(FUP) long enough 
for outcomes to 
occur  
? 
Inadequate – unclear as to 
duration of FUP.  
0 
Inadequate - Unable to 
determine period of follow-up 
E3 - Adequacy of 
follow up of 
cohorts  
1 
All data accounted for, no 
evidence of inadequate FUP.  
0 
Inadequate- insufficient 
information to determine 
adequacy of follow-up of 
cohorts 
 
















of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of participants. 
S3 - Ascertainment 
of exposure 
? 
Inadequate – Unclear as to where 






review, timing of review, 
data sources used and data 
extraction method. 
S4 - Demonstration 
that outcome of 
interest was not 




Description of review for ADR at 
admission. 
1 
Description of review for 
ADR at admission.  
E1 - Assessment of 
outcome  
? 
Inadequate – unclear of how 
outcomes were assessed. 
1 
Description of method of 
ADR identification, collection 
of pertaining details, and 
attending physician 
evaluation. 
E2 - Was follow-up 
(FUP) long enough 
1 
Description of FUP from 
admission until discharge.  
1 
Description of FUP from 
admission until discharge, 
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for outcomes to 
occur  
patients were followed up 












Corsonello 13  
2009  
Justification 
E3 - Adequacy of 
follow up of 
cohorts 
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All patients followed for 
duration of admission, then 
up to 1 year. 
Missing data - some 
outcome data missing but 
accounted for by author 
 

















of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
? 
Description of population, 
setting, duration of study. 
However selection of 
participants was unclear.  
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study. 
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 
sources used and data extraction 
method. 
? 
Detailed description of 
variables of interest. 
However, unclear as to how 
information was obtained, by 
whom and from which source  
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
1 
Description of review for ADR at 
admission. 
1 
Description of review for ADR 
at admission. 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation. 
0 
Details pertaining to AR 
scoring systems are listed. 
However, there is inadequate 
detail as to by whom and 
from which source the 
assessment was conducted. 
E2 - Was follow-up 
(FUP) long enough 
for outcomes to 
occur  
1 
Description of FUP from 
admission until discharge. 
1 
Description of FUP from 
admission until discharge.  
E3 - Adequacy of 
follow up of 
cohorts 
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate FUP. 
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of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study and 
selection of participants.  
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study and 
selection of participants.  
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 





timing of review, data sources 
used and data extraction 
method. 
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
1 
Additional data provided to 
authors demonstrates 
differentiation between pre-
hospital and in-hospital ADRs.  
1 
Additional data provided to 
authors demonstrates 
differentiation between pre-
hospital and in-hospital ADRs. 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation. 
? 
Unclear - scoring systems are 
mentioned, no information in 
paper or the supplied 
additional data explains how 
the outcomes were assessed.  
E2 - Was follow-up 
long enough for 
outcomes to occur  
1 
Description of FUP from 
admission until discharge. 
0 
Inadequate - no mention in 
methods 
E3 - Adequacy of 
follow up of 
cohorts 
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate FUP. 
 





Ganeva 15  
2007  
Justification 
Giardina 28  
2018 
Judgement 





of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 





personnel conducting review, 
data sources used and data 
extraction method. 
S4 - Demonstration 
that outcome of 
interest was not 
1 
Description of review for ADR at 
admission. 
1 
Description of review for ADR 
at admission. 
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Ganeva 15  
2007  
Justification 
Giardina 28  
2018 
Judgement 
Giardina 28  
2018  
Justification 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation.  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation.  
E2 - Was follow-up 
long enough for 
outcomes to occur  
0 
Inadequate - no mention in 
methods 
1 
Description of FUP from 
admission until discharge.  
E3 - Adequacy of 
follow up of 
cohorts  
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate FUP. 
 






Gonzalez-Martin 18  
1997  
Justification 
Hailu 19  
2020 
Judgement 





of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 
sources used and data extraction 




data sources used and 
data extraction method. 
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
0 
Inadequate - no mention of 
assessment of ADRs prior to 
admission. 
0 
Inadequate - no mention 
of assessment of ADRs 
prior to admission. 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and evaluation. 
(source was referenced) 
1 
Description of method of 
ADR identification, 
collection of pertaining 
details, method of 
assessment and 
evaluation. 
E2 - Was follow-up 
long enough for 
outcomes to occur  
0 
Inadequate - No description of 
period of follow-up reported. 
0 
Inadequate - No 
description of period of 
follow-up reported. 
E3 - Adequacy of 
follow up of 
cohorts  
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate 
FUP. 
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Harugeri 29  
2011  
Justification 
Kaur 20  
2018 
Judgement 





of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 






review, timing of review, 
data sources used and 
data extraction method.  
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
0 
Inadequate - no mention of 
assessment of ADRs prior to 
admission. 
0 
Inadequate - no mention 
of assessment of ADRs 
prior to admission. 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation.  
1 
Description of method of 
ADR identification, 
collection of pertaining 
details, assessment and 
evaluation.  
E2 - Was follow-up 
long enough for 
outcomes to occur  
1 
Description of FUP from 
admission until discharge. 
1 
Description of FUP from 
admission until discharge. 
E3 - Adequacy of 
follow up of 
cohorts 
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All patients followed until 
discharge. 
Missing data - some 
outcome data missing but 
accounted for by author 
 
Lavan 2017, Leach 1986 
Description  
Lavan 30   
2017 
Judgement 
Lavan 30  
2017  
Justification 
Leach 21  
1986 
Judgement 





of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 






review, timing of review, 
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data sources used and 
data extraction method. 
Contd. 
Description  
Lavan 30   
2017 
Judgement 
Lavan 30  
2017  
Justification 
Leach 21  
1986 
Judgement 
Leach 21  
1986  
Justification 
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
1 
Events were classified as 
prevalent if they occurred prior 
to enrolment and as incident if 
they occurred after enrolment. 
0 
Inadequate - no mention 
of assessment of ADRs 
prior to admission. 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation.  
? 
Unclear - methods outline 
a definition, probability of 
causality and severity 
criteria for ADRs. 
However, there it is 
unclear as to who 
conducted the 
assessment. 
E2 - Was follow-up 
long enough for 
outcomes to occur  
1 
Description of FUP from 
admission until discharge or 
within 14 days of enrolment, 
whichever came first.  
0 
Inadequate - No 
description of period of 
follow-up reported. 
E3 - Adequacy of 
follow up of 
cohorts 
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate 
FUP. 
 
Liao 2019, Mohebbi 2010 
Description  
Liao 31  
2019 
Judgement 
Liao 31  
2019  
Justification 
Mohebbi 32  
2010 
Judgement 





of the exposed 
cohort 
1 
Retrospective identification from 
established database* 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Retrospective identification from 
established database. Description 
of population, setting, duration of 
study and selection of 
participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S3 - Ascertainment 
of exposure 
1 
Description of established 





review, timing of review, 
data sources used and 
data extraction method. 
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
0 
Inadequate - no mention of 
assessment of ADRs prior to 
admission. 
0 
Inadequate - no mention 
of assessment of ADRs 
prior to admission. 
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E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation. 
? 
Unclear – methods outline 
ADR scoring systems. 
Inadequate detail as to by 




Liao 31  
2019 
Judgement 
Liao 31  
2019  
Justification 
Mohebbi 32  
2010 
Judgement 
Mohebbi 32  
2010  
Justification 
E2 - Was follow-up 
long enough for 
outcomes to occur  
1 
Description of FUP from 
admission until discharge. 
0 
Inadequate - No 
description of period of 
follow-up reported. 
E3 - Adequacy of 
follow up of 
cohorts  
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate 
FUP. 
*Liao et al. was subsequently excluded from analyses based on concerns regarding potential reporting bias in the accuracy of the reported 
ADR rates in the database it was conducted from 
















of the exposed 
cohort 
? 
Description of population, 
setting, duration of study. 
However, selection of 200 
participants is unclear.   
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S3 - Ascertainment 
of exposure 
0 
Inadequate – solely patient 
reported ADRs. No Description of 
objective patient/episode review; 
personnel conducting review, 
timing of review, data sources 





review, timing of review, 
data sources used and 
data extraction method. 
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
0 
Inadequate - no mention of 
assessment of ADRs prior to 
admission. 
0 
Inadequate - no mention 
of assessment of ADRs 
prior to admission. 
E1 - Assessment of 
outcome  
? 
Methods detail “discussion” 
between researcher and doctor 
after patient reports ADR. 
Unclear method of assessment 
and evaluation. 
1 
Description of method of 
ADR identification, 
collection of pertaining 
details, method of 
assessment and 
independent evaluation. 
E2 - Was follow-up 
long enough for 
outcomes to occur  
0 
Inadequate - No description of 
period of follow-up reported. 
0 
Inadequate – FUP on day 5 
and day 10. Potential for 
ADRs to occur after this 
and prior to discharge. 
E3 - Adequacy of 
follow up of 
cohorts 
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate 
FUP. 
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Onder 24  
2010  
Justification 
Reichel 26  
1965 
Judgement 





of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 
selection of participants. 
1 
Description of population, 
setting, duration of study 
and selection of 
participants. 
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 
review, timing of review, data 





timing of review, data 
sources used and data 
extraction method. 
S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
1 
Description of review for ADR at 
admission. ADRs that were 
observed at hospital admission or 
that caused hospital admission 
were excluded.  
1 
Description of review for 
ADR at admission. “the 
development of a new 
problem that was not 
present at the time of 
admission. “ 
E1 - Assessment of 
outcome  
0 
Inadequate – methods detail ADR 
scoring systems. Inadequate 
detail as to by whom the 
assessment was conducted and 
evaluation. 
1 
Description of method of 
ADR identification, 
method of assessment and 
evaluation. 
E2 - Was follow-up 
long enough for 
outcomes to occur  
1 
Description of FUP from 
admission until discharge. 
1 
Description of FUP from 
admission until discharge. 
E3 - Adequacy of 
follow up of 
cohorts  
1 
All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, no 
evidence of inadequate 
FUP. 
 
















of the exposed 
cohort 
1 
Description of population, 
setting, duration of study and 




duration of study and 
selection of participants. 
S2 - Selection of 
the non exposed 
cohort 
1 
Description of population, 
setting, duration of study and 




duration of study and 
selection of participants. 
S3 - Ascertainment 
of exposure 
1 
Description of patient/episode 
review; personnel conducting 





review, timing of review, 
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sources used and data 
extraction method. 
data sources used and 















S4 - Demonstration 
that outcome of 
interest was not 
present at start of 
study 
0 
Inadequate - no mention of 
assessment of ADRs prior to 
admission. 
0 
Inadequate - no mention 
of assessment of ADRs 
prior to admission. 
E1 - Assessment of 
outcome  
1 
Description of method of ADR 
identification, collection of 
pertaining details, method of 
assessment and independent 
evaluation. 
1 
Description of method of 
ADR identification, 
collection of pertaining 
details, method of 
assessment and 
independent evaluation. 
E2 - Was follow-up 
long enough for 
outcomes to occur  
1 
Description of FUP from 
admission until discharge. 
1 
Description of FUP from 
admission until 
discharge. 
E3 - Adequacy of 
follow up of 
cohorts  
1 
 All data accounted for, no 
evidence of inadequate FUP. 
1 
All data accounted for, 
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Appendix 4. Summary of Observational Studies Quality Assessment  
Quality / Risk of Bias assessment based on Modified Newcastle-Ottawa Scale [NOS] domains. 
 
 




















































































































































































































Ayub7 2009 + + + - + + + 6 
0.07  
(0.03-0.14) 
Bowman8  1996 + + + + + + + 7 
0.30  
(0.24-0.35) 
Calderon-Ospina9 2010 + + + + + ? + 6 
0.23  
(0.12-0.37) 
Choeng10,11 2018 ? + - - ? - - 1 
0.69  
(0.61-0.77) 
Conforti12 2012 + + ? + ? + + 5 
0.25  
(0.22-0.28) 
Corsonello13 2009 + + + + + + + 7 
0.11  
(0.09-0.15) 




Regueiro27 2011 ? + ? + - + + 4 
0.12  
(0.07-0.21) 
Ganeva16 2016 + + + + + + + 7 
0.05  
(0.02-0.09) 
Ganeva17 2013 + + + + ? - + 5 
0.09  
(0.06-0.14) 
Ganeva15  2007 + + + + + - + 6 
0.06  
(0.03-0.10) 
Giardina28 2018 + + + + + + + 7 
0.03  
(0.03-0.04) 
Gonzalez-Martin18 1997 + + + - + - + 5 
0.33  
(0.24-0.43) 
Hailu19 2020 + + + - + - + 5 
0.02  
(0.01-0.07) 
Harugeri29 2011 + + + - + + + 6 
0.30  
(0.26-0.35) 
Kaur20 2018 + + + - + + + 6 
0.15  
(0.12-0.19) 
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Lavan30 2017 + + + + + + + 7 
0.22  
(0.18-0.25) 
Leach21 1986 + + + - ? - + 4 
0.19  
(0.15-0.23) 
Liao*31 2019 + + + - + + + 6 
0.01 
(0.01-0.01) 
Mohebbi32 2010 + + + - ? - + 4 
0.23  
(0.17-0.29) 
Mugosa33 2015 ? + - - ? - + 2 
0.42  
(0.30-0.55) 
O'Connor22 2012 + + + - + - + 5 
0.26  
(0.23-0.30) 
Onder24 2010 + + + + - + + 6 
0.07  
(0.06-0.07) 
Reichel26 1965 + + + + + + + 7 
0.11  
(0.08-0.14) 
Tangiisuran34 2012 + + + - + + + 6 
0.13  
(0.11-0.16) 
Tangiisuran35 2014 + + + - + + + 6 
0.12  
(0.10-0.14) 
+  green indicates study was awarded item on assessment low risk of bias; ? yellow indicates description of the item was unclear unclear 
risk of bias; - red - indicates the item was not described high risk of bias; italics identifies studies where all participants were ≥ 65 years. 
*Liao et al. was subsequently excluded from analyses based on concerns regarding potential 
reporting bias in the accuracy of the reported ADR rates in the database it was conducted from i.e. 
retrospective study retrospective based on all reported ADR cases over 6 year period in a single 
medical centre. It is well established that ADRs are consistently underreported and potentially only 
6% of true ADRs are recorded in reporting systems.36  
 




Appendix 5. Observational studies grouped by study quality (p=0.003) 
 
Low – low risk of bias/good quality. High – high risk of bias/poor quality 





Appendix 6. Forrest plot showing proportion of patients aged 65 years or older experiencing an in-hospital ADR - including Liao et 
al.*31 
 
Pooled estimate by random effects (RE) model 0.1423 (0.0970-0.2039) I2=99.15% 2=1.28 
*Liao et al. was subsequently excluded from analyses based on concerns regarding potential reporting bias in the accuracy of the reported ADR rates in the 
database it was conducted from i.e. retrospective study retrospective based on all reported ADR cases over a 6 year period in a single medical centre. It is 
well established that ADRs are consistently underreported and potentially only 6% of true ADRs are recorded in reporting systems.36 




Appendix 7. Observational studies grouped according to NOS Domain S4 - demonstration that outcome of interest (ADR) was not 
present at start of study 
 
Clearly incident – study illustrated that ADRs were not present at admission/enrolment into study; Not clearly incident – study did not adequately describe 
if ADRs were present at admission/enrolment 
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Appendix 8. Funnel plots of included studies  
Funnel plot excluding Liao et al.31
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Appendix 9. Cochrane Risk of Bias (RoB) 2.0 Assessment of Randomised Control Trials 
(RCT). 
Description 
O'Connor 23  
2016 
Judgement Justification (O'Connor23) 
O'Sullivan25  
2016  




Unclear risk of 
bias 
Quote: Two lists of attending consultants were 
generated such that the combined rates of 
ADRs in these groups were known to be 
comparable from an ADR assessment study 
completed shortly before the initiation of the 
present clinical trial. Having finalized the 
composition of the lists, one list of specialist 
consultants was assigned as the intervention 
arm of the study and the other list of specialist 
consultants as the control arm. Comment: no 
evidence of random sequence generation 
Unclear risk of 
bias 
Quote: we generated two clusters 
of attending consultants… one 
group (cluster) of specialist 
consultants was allocated the 
intervention arm of the study 
while the other group (cluster) of 
specialist consultants was 
allocated the control arm. 
Comment: no evidence of random 
sequence generation 
Allocation 
concealment Low risk of bias 
Quote: to avoid potentially biased selection of 
subjects into either arm of the study, we 
approached prospective trial participants in the 
order of their admission to the hospital 
Comment:  Low risk of bias 
Quote: to avoid potentially biased 
selection of subjects into either 
arm of the study, the primary 
researcher approached 
prospective trial participants in 
the order of their admission to the 





should be made 
for each main 
outcome (or class 
of outcomes). 
High risk of 
bias 
Quote: cluster RCT design was chosen for two 
reasons, namely the intervention could not be 
double blinded (because of its nature) and the 
need to avoid possible "training effect". MNO'C 
recruited and conducted intervention and then 
screened for outcome. High risk of bias  
Primary researcher who recruited 
patients was the same researcher 
who carried out the intervention, 





should be made 
for each main 
outcome (or class 
of outcomes). Low risk of bias 
Quote: The primary researcher judged whether 
an ADR had occurred… and corroboration of the 
clinical event or observation by a second 
researcher who was blinded to the 
randomization group of the participant 
Unclear risk of 
bias 
Quote: the research pharmacist 
performed ADR ascertainment… a 
physician trained in geriatric 
pharmacology / therapeutics 
reviewed and verified all putative 
ADRs… subsequently two 
experienced pharmacists verified 





should be made 
for each main 
outcome (or class 
of outcomes). Low risk of bias 
All patients included in reporting including 
those who died during their hospitalisation Low risk of bias 
All patients included in reporting 
including those who died during 
their hospitalisation 
Selective 
reporting Low risk of bias 
Authors reported data on each outcome from 
the aims Low risk of bias 
Authors reported data on each 
outcome from the aims 
Other sources of 
bias N/A - N/A - 
     
Green – low risk of bias, yellow – unclear of risk of bias, red high risk of bias 
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Regression diagnostics illustrating the pooled estimates when excluding one study at a time – these 
values do not change considerably therefore no one study is highly influential.  
4 = Cheong (2018)10,11, 12 = Giardina (2018)28, 23 = Onder (2010)24 
 
  




Subgroup Analyses  
Appendix 10. Reported ADR events and ADR proportions for all included papers/studies, grouped by specialist service setting 
(p=0.051) 
  




Description of ADR Identification and Assessment Methodologies Employed by all Included Papers/studies 
Appendix 11. Description of ADR Identification and Assessment Methodologies Employed by all Included Papers/studies 
Author Year ADR 
Definition 
Identification Method Causality Severity Classification Preventability  
Ayub7 2009 WHO Pharmacist, chart review at 3 TPs, 
adapted from National Health 
Surveillance Agency 
Naranjo Not documented Rawlins & 
Thompson 
Not documented 
Bowman8 1996 Local 
therapeutic 
committee 
2 x Pharmacist, chart review, ≥ 3 TPs, 
indicator flag list and spontaneous 
reporting 
Naranjo Venulet Rawlins & 
Thompson 
Not documented 
Calderon-Ospina9 2010 WHO 2 x two internal physicians, daily 
assessment, patient questioning and 
panel adjudication  
WHO-UMC Author defined DoTS Schumock & 
Thornton 
Cheong10,11 2018 Not 
Documented 
Retrospective chart review Naranjo Hartwig Not 
documented 
Not documented 
Conforti12  2012 Edwards & 
Aronson 




WHO-ART WHO-ART Not documented 
Corsonello13 2009 WHO Physician, daily review of chart, 
laboratory results, discussion with 
nurse and attending physician. 
Not 
documented 
Author defined Not 
documented 
Not documented 
Davies14 2009 Edwards & 
Aronson 
Research pharmacist, daily review 
patients’ drug charts, medical and 
nursing notes. 
Naranjo Hartwig Rawlins & 
Thompson 
Hallas 


















Ganeva15 2007 WHO 3 x Dermatologist and pharmacologist, 
Structured review past medical and 
drug history, laboratory tests, clinical 
description of adverse event and 
outcome.  
Naranjo Author defined WHO-ART & 
Rawlins 
Not documented 
Ganeva17 2013 WHO Medical chart review Naranjo author defined – “clinical 
judgement" mild, moderate, 
severe" 
WHO-ART Not documented 
Ganeva16 2016 WHO Screened during clinical rounds, 
analysis of laboratory data. 
Naranjo Hartwig WHO-ART Hallas 
Giardina28 2018 Not 
documented 
Medical records screened by 
pharmacist, then research team review 





defined - prior 
publication 
The pharmacovigilance described by 
the Boston Collaborative Drug 
Surveillance Program 





Hailu19 2020 WHO Four MSc clinical pharmacists identified 
and documented DRPs (patient 
questionnaire and chart review. 
Naranjo Hartwig Rawlins & 
Thompson 
Not documented  
Harugeri29 2011 WHO Pharmacist, daily review of chart, 
laboratory and nursing notes. 
Naranjo Hartwig WHO-ART Not documented 








Identification Method Causality Severity Classification Preventability  
Kaur20 2018 Edwards & 
Aronson’s  
Spontaneous reporting, chart and 
laboratory results review then  
geriatrician physician and 
pharmacologist assessment 
Naranjo Hartwig Rawlins & 
Thompson 
Not documented 
Lavan30 2017 WHO Application of trigger list at recruitment 
and then retrospectively at D14/DC, all 
cases adjudicated 
WHO-UMC Hartwig Not 
documented 
Not documented 
Leach21 1986 WHO Patient interview and notes review Kramer Hurwitz Rawlins & 
Thompson 
Not documented 
Liao31 2019 Edwards & 
Aronson’s 
Interrogation of ADR reporting 
database (ADRs approved by senior 
pharmacist) 
Naranjo Not documented Not 
documented 
Not documented  
Mohebbi32 2010 WHO Pharmacist; daily patient interview, 
chart and lab results review; 
confirmatory discussion with physicians 
WHO-UMC WHO-ART Not 
documented 
Not documented 
Mugosa33 2015 WHO SPC/ADR specific questionnaire and 
patient interview, discussion between 
interviewer and physician 




O’Connor22 2012 Not 
Documented 
Physician; review of medications labs 
and notes at D5 & D10; patient and 
physician consultation 













Identification Method Causality Severity Classification Preventability  
O’Connor23 2016 WHO Not documented WHO-UMC Author defined Not 
documented 
Hallas 
Onder24 2010 WHO Physician; daily review of nursing and 
medical notes 
Naranjo Author defined Not 
documented 
Not documented 
O’Sullivan25 2016 WHO Pharmacist; D7-10/DC interview with 
patient or NOK; review of notes, labs, 
Kardex® and trigger list. ADRs 
adjudicated by geriatrician. 
WHO-UMC Hartwig Not 
documented 
Not documented 




Physician; daily chart review - labs, 
medical and nursing notes, Kardex®, 
investigations, autopsy reports  
Not 
documented 
Not documented Not 
documented 
Not documented 
Tangiisuran34 2012 Edwards & 
Aronson 
3 step process – identify, confirm and 
classify; daily review of labs, notes, 
prescriptions  
Hallas Morimoto Rawlins & 
Thompson 
Hallas 




Primary investigator trigger tool and 
review of medical and nursing notes, 
labs, drug charts and incident forms 
Hallas D 
Naranjo V 
Not documented Not 
documented 
Not documented 
WHO – World Health Organisation, TP – Time point WHO-UMC – World Health Organisation Uppsala Monitoring Centre, DoTs – Dose, time and susceptibility classification, 
WHO-ART – World Health Organisation Adverse Drug Reaction Terminology, EMA - European Medicines Agency, MedDRA-SOC® - Medical Dictionary for Regulatory Activities 




System Organ Classes, D – Day, DC – Discharge, SPC – Summaries of Product Characteristics, NOK – next of kin,   D – development group, V – validation group, DoTs –.; DRPs – 
drug related problems. 
Definitions  
WHO37 “a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for 
the modification of physiological function.”  
Edwards and Aronson38 "an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from 
future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product." 
Bates39 “Adverse drug event - An injury resulting from medical intervention related to a drug.” 
 
Causality 
Naranjo40 definite, probable, possible, doubtful. Event scored across 10 questions (answers Yes, No, Don’t Know) Total scores range from -4 to +13; ≥9 indicates a definite 
adverse drug reaction (ADR); a score of 5 to 8 indicates a probable ADR; a score of 1 to 4 indicates a possible ADR; a score of ≤ 0 indicates that an ADR is doubtful. Q1 Are 
there previous conclusive reports on this reaction? (+1, 0, 0) Q2 Did the adverse event occur after the suspected drug was administered? (+2, -1, 0) Q3 Did the adverse reaction 
improve when the drug was discontinued or an antagonist was administered? (+1, 0, 0) Q4 Did the adverse reaction reappear when the drug was re-administered? (+2, -1, 0) 
Q5 Are there alternative causes (other than the drug) that could have on their own caused the reaction? (-1, +2, 0) Q6 Did the reaction reappear when a placebo was given? 
(-1, +1, 0) Q7 Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? (+1, 0, 0) Q8 Was the reaction more severe when the drug was increased 
or less severe when the drug was decreased? (+1, 0, 0) Q9 Did the patient have a similar reaction to the same or similar drugs in any previous exposure? (+1, 0, 0) Q10 Was 
the adverse event confirmed by any objective evidence? (+1, 0, 0)  
WHO-UMC41 Certain, probable, possible, unlikely, conditional/ unclassified, unassessable/ unclassifiable. Certain – event / laboratory test abnormality with plausible time 
relationship to intake of a drug, cannot be explained by disease or other drugs, response to withdrawal plausible, event definitive pharmacologically or phenomenologically, 
rechallenge satisfactory, if necessary. Probable – event or laboratory test abnormality, with reasonable time relationship to drug intake, unlikely to be attributed to disease 




or other drugs, response to withdrawal clinically reasonable, re-challenge not required. Possible – event or laboratory test abnormality, with reasonable time relationship to 
drug intake, could also be explained by disease or other drugs, information on drug withdrawal may be lacking or unclear. Unlikely – Event or laboratory test abnormality, 
with a time to drug intake that makes a relationship improbable Disease or other drugs provide plausible explanations. Conditional/ Unclassified – event or laboratory test 
abnormality, more data for proper assessment needed, or additional data under examination. Unassessable/ Unclassifiable – report suggesting an adverse reaction, cannot 
be judged because information is insufficient or contradictory, data cannot be supplemented or verified. 
Hallas42 Definite (all five criteria were satisfied), probable (criteria (l), (2), (3) and (4) were satisfied), possible (criteria (1), (2) and (3) were satisfied) and unlikely/unevaluable 
(The relevant information required for evaluation could not be obtained, or the temporal sequence was atypical, or other conditions or dispositions were considered far more 
likely to have caused the symptoms); Criteria –  (1) known ADR or toxic reaction: (2) a reasonable temporal relationship between commencement of drug therapy and onset 
of adverse reaction : (3) the adverse reaction disappeared upon dis- continuation or dose reduction: (4) the symptom or event could not be explained by any other known 
condition or predisposition of the patient: (5) the symptoms reappeared upon re-exposure, or laboratory tests showed toxic drug levels or drug-induced metabolic disturbances 
that explained the symptom.  
Kramer43 definite (score 6-7), probable (score 4-5), possible (0-3), unlikely (<0) based on a multi-axis algorithm, six axes are scored and the individual scores are added to get 
a total score, which corresponds to an overall probability that the clinical manifestation represents an ADR. The total score can range from -7 to +7.  
 
Severity 
Hartwig44 seven level scale, mild (levels 1 & 2), moderate (levels 3 & 4) and severe (levels 5, 6 & 7); 1 An ADR occurred but no change in treatment with suspected drug 2 The 
ADR required that treatment with the suspected drug be held, discontinued or otherwise changes. No antidote or other treatment required. No increase in length of stay. 3 
The ADR required that treatment with the suspected drug be held, discontinued or otherwise changed, or an antidote or other treatment. No increase in length of stay. 4 Any 
level 3 ADR which increases length of stay by at least one day or the ADR was the reason for admission. 5 Any level 4 ADR which required intensive medical care. 6 Any ADR 
causing permanent harm to the patient. 7a The ADR was indirectly linked to the death of the patient. 7b The ADR was directly linked to the death of the patients. 
Hurwitz45 Severe: fatal or life threatening, (2) moderate: required treatment, admission to hospital, or prolonged the stay in hospital by at least one day, (3) mild: incidental, 
required no treatment.  




Morimoto46 four discrete categories: (a) fatal, i.e. leading to death; (b) life threatening, i.e. prolonging hospitalization, leading to permanent defects or life-threatening 
complications; (c) serious, i.e. demanding a dosage reduction, therapy cessation etc.; or (d) significant, i.e. any ADR that does not meet the above criteria, not usually requiring 
a change in therapy.  
Venulet47 Severe: Fatal or life threatening, lowers the patient's life expectancy. A severe impairment of a vital organ-system, even if transient. Persisting for more than one 
month period. Moderate: Symptoms are marked but involvement of vital organ-systems is moderate. No loss of consciousness, no cardiovascular failure. Antidote drugs or 
hospizalization required or hospitalization prolonged by at least one day. Development of definite biochemical or structural changes could justify assigning to this category. 
Minor: Incidental, no antidote required, suspected drug mayor may not be stopped. Do not complicate significantly the primary disease.  
WHO-ART48 Non-serious or Serious: An adverse event or reaction that results in death; requires hospitalization or extension of hospital stay; results in persistent or significant 
disability or incapacity; is life-threatening.  
European Medicines Agency49 serious if fatal, life-threatening, required or prolonged hospitalization, caused serious or permanent disability, or congenital anomaly/birth 
defect.  
Spanish system of pharmacovigilance50 Mild (no additional measures required), moderate (motivates hospital admission), severe (threatens the patient's life) and deadly 
(contributes directly or indirectly to Patient's death). 
 
Classification 
DoTs9 three-dimensional classification - Dose, timing and susceptibility classification; Dose – (1) supratherapeutic reactions (occurring at doses higher than are recommended), 
(2) collateral reactions (which usually occur at the recommended dose) or (3) hypersensitivity reactions (occurring at lower doses than are recommended); Timing - : (1) fast 
reactions (on administration of a drug, which is usually given intravenously), (2) the first dose, (3) early, (4) intermediate, (5) late and (6) delayed; Susceptibility –  factors of 
genetic susceptibility, age (paediatric and older population), gender and the presence of exogenous factors (e.g. drug interactions) or disease (e.g. hepatic or renal disease).  
MedDRA-SOC®6 five level hierarchy from very specific (lowest level terms of which there are 70,000) to very general (system organ class).  




Rawlins and Thompson51 divided into two categories: reactions that are common, predictable, and that may occur in any individual (type A); and reactions that are uncommon, 
not predictable, and that occur only in susceptible individuals (type B). 
WHO-ART48 four level hierarchy from general system organ classes (32), high level terms, preferred terms, and included terms (no longer actively maintained, last release 
WHO-UMC 2015, and superseded by MedDRA-SOC® in 2008).  
Meyboom52 type A ("drug actions"), type B ("patients reactions") and type C ("statistical "). 
 
Preventability 
Hallas42 definitely avoidable, possibly avoidable, unavoidable and unclassifiable – ‘Definitely avoidable’. The drug event was due to a drug treatment procedure inconsistent 
with present- day knowledge of good medical practice or was clearly unrealistic, taking the known circumstances into account. ‘Possibly avoidable ’. The prescription was not 
erroneous, but the drug event could have been avoided by an effort exceeding the obligatory demands. ‘Not avoidable’. The drug event could not have been avoided by any 
reasonable means, or it was an unpredictable event in the course of a treatment fully in accordance with good medical practice. ‘Unevaluable’ . The data for rating could not 
be obtained or the evidence was conflicting.  
Schumock & Thornton53 certainly preventable, probably preventable, unavoidable/not preventable; yes to any question in any category. Definitely preventable 1. Was there 
a history of allergy or previous reactions to the drug? 2. Was the drug involved inappropriate for the patient’s clinical condition? 3. Was the dose, route or frequency of 
administration inappropriate for the patient’s age, weight or disease state? 4. Was a toxic serum drug concentration (or laboratory monitoring test) documented? 5. Was 
there a known treatment for the Adverse Drug Reaction? Probably preventable 6. Was required Therapeutic drug monitoring or other necessary laboratory tests not 
performed? 7. Was a drug interaction involved in the ADR? 8. Was poor compliance involved in the ADR? 9. Were preventative measures not prescribed or administered to 
the patient? Unavoidable/Not preventable If all above criteria not fulfilled 
 




Appendix 12. Meta-analysis of Studies Where all Participants Were ≥65 Years at Baseline (p=0.299) 
  
RE – Random effects model  
eFigure 2: Subgroup analysis of patients experiencing at least one in-hospital ADR in studies recruiting all ages7-9,14-20,28,29,32,33 versus solely ≥65 years.10-13,21-
27,30,35  
RE – Random effects model, n – number of patients aged ≥65 years, n ADR – number of patients ≥65 years experiencing at least 1 ADR during hospitalisatio 




Appendix 13.  Meta-analysis of studies grouped by ADR definition (p=0.806) 
 




Appendix 14. Meta-analysis of studies grouped by ADR causality (p=0.78) 
 




Appendix 15. Meta-analysis of studies grouped by comparable overlapping ADR methodologies (p=0.383) 
 
 
eFigure: Forest plot showing subgroup analysis of prevalence of in hospital ADRs reported by studies grouped by matching assessment methods 




Appendix 16. Pooled estimates of ADR proportions grouped by ADR identification methods (p =0.31) 
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ADR Presentations  
Appendix 17. Ranking of ADR Presentations by MedDRA-SOC® Classification 
 
Rank 
MedDRA® SOC Classification n 
% of 
2728 cumulative 
1 Gastrointestinal Disorders 629 23.05% 23.06% 
2 Metabolism and Nutrition Disorders 565 20.73% 43.77% 
3 Unclassifiable - Unclassifiable (Grouped Presentations / "Other") 397 14.57% 58.32% 
4 Vascular Disorders 216 7.93% 66.24% 
5 Cardiac Disorders 187 6.86% 73.09% 
6 Renal and Urinary Disorders 175 6.42% 79.51% 
7 Investigations 116 4.26% 83.76% 
8 Infections and Infestations 87 3.19% 86.95% 
9 Skin and Subcutaneous Tissue Disorders  72 2.64% 89.59% 
10 Blood and Lymphatic System Disorders 61 2.24% 91.83% 
11 Psychiatric Disorders 58 2.13% 93.95% 
12 Nervous System Disorders 56 2.02% 96.00% 
13 Injury, Poisoning and Procedural Complications 48 1.72% 97.76% 
14 Respiratory, Thoracic and Mediastinal Disorders 23 0.84% 98.61% 
15 Musculoskeletal and Connective Tissue Disorders 12 0.44% 99.05% 
16 General Disorders and Administration Site Conditions 9 0.33% 99.38% 
17 Immune System Disorders 8 0.29% 99.67% 
18 Hepatobiliary Disorders 5 0.18% 99.85% 
19 Eye Disorders 4 0.15% 100.00% 
    2728 100.00%  












n Further ADR Description n 
Lowest Level ADR 





Gastrointestinal motility and 
defaecation conditions  
392 
Constipation 254 - - 
Diarrhoea 138 - - 
Unspecified / unclassifiable 
Gastrointestinal disorders 
90 
Gastrointestinal  88 - - 
Vomiting and diarrhoea 2 - - 
Gastrointestinal 
haemorrhages NEC  
67 
GI Bleed 60 - - 
Gastrointestinal bleeding 7 - - 
Gastrointestinal signs and 
symptoms  
61 
Nausea / vomiting 59 - - 
Dyspepsia 2 - - 
Gastrointestinal stenosis and 
obstruction  




Haemorrhage / gastritis 6 - - 
Gastritis 1 - - 








Potassium imbalance 299 
Hypokalaemia 275 
Hyperkalaemia 24 
Sodium imbalance 29 
Hyponatraemia 27 
Hypernatraemia 2 
Total fluid volume 
decreased  
2 Dehydration 2 
Total fluid volume 
increased  
3 Oedema 3 
Unspecified / 
unclassifiable - 
Electrolyte and fluid 
balance conditions  
128 
  
Electrolyte disturbance 78 
Electrolytic  50 











n Further ADR Description n 
Lowest Level ADR 






Bone, calcium, magnesium 
and phosphorus metabolism 
disorders  
3 
Hypercalcaemia 2 - - 
  
Unspecified / 
unclassifiable - Bone, 







Unspecified / unclassifiable - 
Metabolism and nutrition 
disorders 
26 
Electrolyte / metabolic 
abnormality 
26 - - 
Glucose metabolism disorders 
(incl. diabetes mellitus)  
74 
Hyperglycaemic 




Steroid diabetes 2 
Hypoglycaemic 
conditions NEC  
51 Hypoglycaemia 51 
Purine and pyrimidine 
metabolism disorders  
1 
Disorders of purine 
metabolism  
1 Hyperuricemia 1 
Unclassifiable  14.55% 397 
Unclassifiable into MedDRA® 
SOC grouping from 




370 - - 
Reported as "other" or 
"missing" 
27 - - 
Vascular disorders 7.92% 216 
Decreased and nonspecific 





126 Hypotension 81 
  Postural hypotension 45 
Vascular haemorrhagic 
disorders 














1 Hypertension 1 -  - 







n Further ADR Description n 
Lowest Level ADR 
Detail (when available) 
n 
Cardiac disorders 6.85% 187 
Rate and rhythm disorders 74  
Bradycardia 55 -  - 
Tachycardia 7 - - 
AV Block 12 - - 





arrhythmic complications  
97 - - 
Cardiovascular system 13 - - 
Cardiac failure 2 
Left ventricular failure / 
overload 
2 - - 
Chest pain 1 Chest pain 1 - - 
Renal and urinary 
disorders 
6.41% 175 
Renal disorders (excl. 
nephropathies)  
150 
AKI 148 AKI 148 
Renal failure 
complications  
2 Hyperazotaemia 2 
Urinary tract signs and 
symptoms 
22 




Urine retention 4 
Nephropathies  3 Nephritis 3 - - 
Investigations 4.25% 116 
Haematology investigations - 




INR increase 97 - - 
Low prothrombin time 1 - - 
Toxicology and therapeutic 





2 - - 
Hepatobiliary investigations - 
liver function analyses 




Fungal infectious disorders - 
Candida infections  
67 Thrush 67 - - 











n Further ADR Description n 
Lowest Level ADR 
Detail (when available) 
n 
Infections and 
infestations contd.  
  
Bacterial infectious disorders - 
Clostridia infections  
19 
Clostridium difficile +ve 
w/o diarrhoea 
7 - - 
Clostridium difficile 
diarrhoea 





acute kidney injury 
4 - - 
C. Diff Colitis 3 - - 
Viral infectious disorders - 
herpes viral infections 
1 Herpes zoster 1 - - 
Skin and subcutaneous 
tissue disorders  
2.64% 72 
Epidermal and dermal 
conditions 
72 
Rashes, eruptions and 
exanthems NEC  
72 
Cutaneous Rash 60 
Prurigo 2 
Urticaria 10 
Blood and lymphatic 
system disorders 
2.24% 61 
Anaemias nonhaemolytic and 
marrow depression 
27 
Anaemia 26 - - 
Pancytopaenia 1 - - 
Platelet disorders  16 Thrombocytopaenia 16 - - 
Unspecified / Unclassifiable 





14 - - 
Coagulation 1 - - 
White blood cell disorders 3 
Neutropenia 2 - - 
Leukopaenia 1 - - 
Psychiatric disorders 2.13% 58 
Deliria (incl. confusion)  52 Confusion 52 -  - 
Disturbances in thinking and 
perception  
6 Hallucination 6 - - 











n Further ADR Description n 
Lowest Level ADR 





Neurological disorders NEC 25 
Disturbances in 








Headaches 9 - - - - 
Unspecified / unclassifiable 
nervous system disorders 
11 Central nervous system 11 - - 
Neurological signs and 
symptoms NEC 
5 Dizziness 5 - - 
Movement disorders (incl. 
parkinsonism)  
3 
Tremor 2 - - 
Extra-pyramidal SEs 1 - - 
Seizures (incl. subtypes)  2 
Non-convulsive epileptic 
crisis 
1 - - 
Seizure 1 - - 
CNS Vascular disorder 1 










Injuries NEC 34 Fall 34 - - 
Bone and joint injuries  2 Fracture 2 - - 
Toxicity to various agents  8 
Digitalis intoxication 6 - - 
Lithium toxicity 1 - - 
Opioid toxicity 1 - - 
Procedural related injuries 
and complications NEC - 
Cardiac and vascular 
procedural complications 
3 Phlebitis 3 - - 
Exposures, chemical injuries 
and poisoning 












Respiratory disorders NEC  20  
Respiratory failures (excl. 
neonatal)  
16 - - 
Cough 4 - - 
Unspecified / unclassifiable 
respiratory system  
3 Respiratory system 3 - - 







n Further ADR Description n 
Lowest Level ADR 






Joint disorders - Crystal 
arthropathic disorders  
8 Gout 8 - - 
Bone disorders (excl. 
congenital and fractures) - 
metabolic bone disorders 
3 Osteoporosis 3 - - 
Muscle disorders 1 Muscular necrosis 1 - - 
General disorders and 
administration site 
conditions 
0.33% 9  
Body temperature conditions  3 Hyperthermia 3 - - 
General system disorders NEC 2 Hyperhidrosis 2 - - 
Asthenic conditions  1 Asthenia 1 - - 
Gait disturbances  1 Ataxia 1 - - 
Inflammations 1 Local inflammation 1 - - 
Therapeutic and 
nontherapeutic effects (excl. 
toxicity)  
1 Signs of withdrawal 1 - - 
Immune system 
disorders 
0.29% 8  Allergic conditions 8 
Allergy or drug sensitivity 7 - - 
Bronchospasm 1 - - 
Hepatobiliary disorders 0.18% 5  
Unspecified / unclassifiable 
Hepatobiliary disorders 
5  
Jaundice 1 -  - 
Hepatic  4 - - 
Eye disorders 0.15% 4 
Glaucoma and ocular 
hypertension  
2 Glaucoma 2 - - 
Anterior eye structural 
change, deposit and 
degeneration 
2 
Cataract 1 - - 
Corneal deposits 1 - - 




NEC – Not elsewhere classified, AV – atrioventricular, AKI – Acute Kidney Injury, INR – International Normalised Ratio, +ve – positive, w/o – without, C. Diff – Clostridium Difficile, Incl. – including, SEs – Side effects, excl. 
– excluding 
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Appendix 19. Causative Drug Agents Ranked by Descending Frequency as per 
Therapeutic Subgroup (ATC 2nd Level). 
Rank ATC 2nd Therapeutic subgroup n 
% of 
2385 
1 C03 Diuretics 473 19.83% 
2 J01 Antibacterials for systemic use 354 14.84% 
3 B01 Anti-thrombotic agents 292 12.24% 
4 N02 Analgesics 260 10.90% 
5 R03 Drugs for obstructive airway diseases 113 4.74% 
6 C09 Agents acting on the renin-angiotensin system 98 4.11% 
7 N05 Psycholeptics 92 3.86% 
8 H02 Corticosteroids for systemic use 77 3.23% 
9 C01 Cardiac therapy 71 2.98% 
10 A10 Drugs used in diabetes  61 2.56% 
11 J04 Anti-mycobacterials 54 2.26% 
12 C02 Anti-hypertensives 52 2.18% 
13 A12 Mineral supplements 50 2.10% 
14 C08 Calcium channel blockers 41 1.72% 
15 M01 Anti-inflammatory and anti-rheumatic products 40 1.68% 
16 N03 Antiepileptics 30 1.26% 
17 A02 Drugs for acid related disorders 26 1.09% 
18 A06 Drugs for constipation 24 1.01% 
19 B03 Antianemic preparations 22 0.92% 
20 N06 Psychoanaleptics 20 0.84% 
21 C07 Beta blocking agents 19 0.80% 
22 B05 Blood substitutes and perfusion solutions 15 0.63% 
23 R01 Nasal preparations 15 0.63% 
24 S02 Otologicals 11 0.46% 
25 M04 Antigout preparations 10 0.42% 
26 C**** Not specified by paper  8 0.34% 
27 C10 Lipid modifying agents 7 0.29% 
28 M05 Drugs for treatment of bone diseases 6 0.25% 
29 N07 Other nervous system drugs 6 0.25% 
30 L01 Antineoplastic agents 5 0.21% 
31 A03 Drugs for functional gastrointestinal disorders 4 0.17% 
32 G04 Urologicals 3 0.13% 





35 J02 Antimycotics for systemic use 2 0.08% 
36 M03 Muscle relaxants 2 0.08% 
37 N**** "Psychotropics" unspecified 2 0.08% 
38 N01 Anaesthetics 2 0.08% 
39 R05 Cough and cold preparations 2 0.08% 
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ATC 2nd Therapeutic subgroup n 
% of 
2385 
40 R06 Antihistamines for systemic use 2 0.08% 
41 A04 Antiemetics and antinauseants 1 0.04% 
42 A11 Vitamins 1 0.04% 
43 D01 Antifungals for dermatological use 1 0.04% 
44 D06 




Pituitary and hypothalamic hormones and 
analogues 
1 0.04% 
46 L04 Immunosuppressants 1 0.04% 
47 P01 Antiprotozoals 1 0.04% 
48 P02 Anthelmintics 1 0.04% 
49 V04 Diagnostic agents 1 0.04% 
 
 
Appendix 20. Reported Causative Drugs Grouped by Anatomical Group (ATC 1st Level) 
in Descending Order. 







C – Cardiovascular System  769 32.24% 
N – Central nervous system  415 17.40% 
J – General anti-infectives, systemic  410 17.19% 
B – Blood and blood forming organs  329 13.79% 
A - Alimentary tract and metabolism 169 7.09% 
R – Respiratory system  132 5.54% 
H – Systemic hormonal preparations, excl. sex hormones  78 3.27% 
M – Musculo-skeletal system 58 2.43% 
S - Sensory organs 11 0.46% 
L - Antineoplastic and immunomodulating agents 6 0.25% 
G – Gentino-urinary system and sex hormones  3 0.13% 
D – Dermatologics 2 0.08% 
P - Antiparasitic products, insecticides and repellents 2 0.08% 
V – Various  1 0.04% 
  2385 100.00% 
 Excl. - excluding 
 




Appendix 21. Breakdown of Causative Drugs by ATC Classification in Descending Frequency – Grouped by Anatomical (ATC 1st) Level 
to Chemical Substance/Drug (ATC 5th); n = 2385. 
Cardiovascular system 
Cardiovascular 769 (32.24%) 











ATC 5th / drug 
(when n ≥ 10) 
n 




























5 - - - - - 
C03* 
Not specified by 
paper 
39 - - - - - 
C09 
Agents Acting On The Renin-
Angiotensin System 
98 
C09A ACE inhibitors, plain 39 C09AA 
ACE inhibitors, 
plain (ramipril ) 
14 Ramipril  14 
C09* 
Not specified by 
paper 





12 - - - - - 
C09D 
ARB II,  
combinations 
1 - - - - - 

















ATC 5th / drug 
(when n ≥ 10) 
n 
C01 Cardiac Therapy 71 
C01A Cardiac glycosides 44 C01AA Digitalis glycosides  39 Digoxin 39 
C01D 
Vasodilators used in 
cardiac diseases 
12 - - - - - 
C01B 
Antiarrhythmics, 




10 Amiodarone 10 
C01* 
Not specified by 
paper 







2 - - 
C02 Antihypertensives 52 C02* 
Not specified by 
paper 
52 - - - - - 
C08 Calcium Channel Blockers 41 
C08* 
Not specified by 
paper 




with direct cardiac 
effects 






4 - - - - - 













2 - - 
C07AG 
Alpha and beta 
blocking agents 
1 - - 
C07C 
Beta blocking 
agents and other 
diuretics 
1 - - - - - 

















ATC 5th / drug 
(when n ≥ 10) 
n 
C**** Not specified by paper  8 - - - - - - - - 
C10 Lipid Modifying Agents 7 C10* 
Not specified by 
paper 
7 - - - - - 
 
Central nervous system 
Central Nervous System 415 (17.40%) 











ATC 5th/ drug 
(when n ≥ 10) 
n 
N02 Analgesics 260 








44 Morphine 40 















N02BE Anilides 34 Co-codamol 31 
N02B* 
Not specifed by 
the paper  
18 - - 
N05 Psycholeptics 92 











1 - - 
N05A Antipsychotics 18 N05A* 
Unspecified 
"Antipsychotics" 
7 - - 




Contd.  ATC 
2nd   











ATC 5th/ drug 








































1 - - 
















2 -  -  
N05CA Barbiturates, plain 1 -  -  








9 -  -  







3 -  -  
Contd.  ATC 
2nd   











ATC 5th/ drug 
(when n ≥ 10) 
N 
N06 Psychoanaleptics 20 




















1 -  -  -  -  -  
N07 Other nervous system drugs 6 -  -  -  -  -  -  -  -  
N**** "Psychotropics" unspecified 2 -  -  -  -  -  -  -  -  
N01 Anaesthetics 2 -  -  -  -  -  -  -  -  
N04 Anti-parkinson drugs 3 -  -  -  -  -  -  -  -  
 
Anti-infectives for systemic use 
Ant-infectives for systemic use 410 (17.19%) 











ATC 5th/ drug 
(when n ≥ 10) 
n 
J01 

















28 Co-amoxiclav 28 







2nd   











ATC 5th/ drug 


















16 Sulbactam 16 
J01C* 
Not specified by 
paper 








9 -  -  
J01* 
Not specified by 
paper 


























J01FA Macrolides 43 
Erythromycin  24 
Clarithromycin  18 
















8 -  -  





2nd   











ATC 5th/ drug 






























6 -  -  -  -  -  
J01A Tetracyclines 1 -  -  -  -  -  










Not specified by 
the paper  
49 
J02 





2 -  -  -  -  -  
 
Blood and blood forming organs 
Blood and blood forming organs 329 (13.79%) 








Chemical Subgroup n 
ATC 5th/ drug 
(when n ≥ 10) 
n 






agents vitamin K 
antagonists 














ATC 2nd   








Chemical Subgroup n 
ATC 5th/ drug 
























B01AD Enzymes 3 -  -  
B01* 
Not specified by 
paper 
18 -  -  -  -  -  
B03 Antianemic Preparations 22 
B03A Iron preparations 20 
B03AA 









4 -  -  
B03* 
Not specified by 
paper 
1 -  -  -  -  -  
B03B 
Vitamin B12 and 
folic acid 
1 -  -  -  -  -  
B05 
Blood Substitutes And 
Perfusion Solutions 
15 B05B I.V. SOLUTIONS 8 -  -  -  -  -  
 
Alimentary tract and metabolism 
Alimentary tract and metabolism 169 (7.09%) 








Chemical Subgroup n 
ATC 5th/ drug 
(when n ≥ 10) 
n 





















ATC 2nd   








Chemical Subgroup n 
ATC 5th/ drug 





























20 -  -  -  -  -  
A10* Not specified 1 -  -  -  -  -  
A12 Mineral Supplements 50 
A12A Potassium 9 -  -  -  -  -  
A12A Calcium 41 A12AA Calcium 41 -  -  
A02 
Drugs for Acid Related 
Disorders 
26 A02B 




26 -  -  -  -  -  








9 -  -  
A06AB Contact laxatives 4 -  -  
A03 
Drugs for Functional 
Gastrointestinal Disorders 









1 -  -  -  -  -  -  -  -  
A11 Vitamins 1 -  -  -  -  -  -  -  -  





Respiratory System 132 (5.53%) 






Chemical Subgroup n 




Drugs For Obstructive Airway 
Diseases 
113 










other drugs, excl. 
anticholinergics 








4 -  -  
R03D 
Other systemic drugs 
for obstructive airway 
diseases 
23 R03DA Xanthines 23 Theophylline 12 
R03B 
Other drugs for 
obstructive airway 
diseases, inhalants 
8 -  -  -  -  -  
R03* Not specified by paper 4 -  -  -  -  -  





15 R01AD Corticosteroids 14 Beclomethasone 14 
R05 Cough And Cold Preparations 2 -  -  -  -  -  -  -  -  
R06 Antihistamines For Systemic Use 2 -  -  -  -  -  -  -  -  
 




Systemic hormonal preparations, excluding sex hormones 
Systemic hormonal preparations, excluding sex hormones 78 (3.27%) 











ATC 5th / drug 








systemic use, plain 
61 
H02AB Glucocorticoids 60 Prednisolone 41 
H02AA Mineralocorticoids 1  - - 
H02* 
Not specified by 
paper 






1 - - - - - - - - 
 
Musculoskeletal system 
Musculo-skeletal system 58 (2.43%) 









ATC 5th / drug 











Not specified by 
the paper  
25 -  -  
M04 Antigout Preparations 10 M04A 
Antigout 
preparations 
10 -  -  -  -  -  
M05 
Drugs For Treatment of 
Bone Diseases 
6 M05B 
Drugs affecting bone 
structure and 
mineralization 
6 M05BA Bisphosphonates 6 -  -  
M03 Muscle Relaxants 2 -  -  -  -  -  -  -  -  
 
Sensory organs  
Sensory organs 11 (0.46%) 















ATC 5th / drug 
(when n ≥ 10) 
n 
S02 Otologicals 11 S02B Corticosteroids 11 S02BA Corticosteroids 11 Dexamethasone 11 
 
Antineoplastic and immunomodulating agents 
Antineoplastic and immunomodulating agents 6 (0.25%) 











ATC 5th / drug 
(when n ≥ 10) 
n 
L01 Antineoplastic Agents 5  - -  -  -  -  -  -  -  
L04 Immunosuppressants 1  - -  -  -  -  - - - 
 
Genitourinary system and sex hormones 
Genito-urinary system and sex hormones 3 (0.13%) 











ATC 5th / drug 
(when n ≥ 10) 
n 
G04 Urologicals 3  - - - - - - - - 
 
Dermatologics 
Dermatologics 2 (0.08%) 











ATC 5th / drug 










1 - - - - - - - - 
 




Antiparasitic products, insecticides and repellents 
Antiparasitic products, insecticides and repellents 2 (0.08%) 











ATC 5th / drug 
(when n ≥ 10) 
n 
P01 Antiprotozoals 1 - - - - - - - - 
P02 Anthelmintics 1 - - - - - - - - 
 
Various 
Various: 1 (0.04%) 











ATC 5th / drug 
(when n ≥ 10) 
n 
V04 Diagnostic Agents 1 - - - - - - - - 
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Appendix 22. ADR Reported Severity. 
Eighteen studies reported details pertaining to ADR severity.8,9,12-17,19-26,31,34 
Author Population n ≥ 65 
# ≥ 65 
ADRs 




Population ≥ 65 
years 
1023 245 Not described 130 53.30 
Corsonello (2009)13 
Population ≥ 65 
years 
506 99 Not described 22/58pts 37.93 
Leach (1986)21 
Population ≥ 65 
years 500 117 Hurwitz 70 59.83 
Liao (2020)31 




Not described 347 64.38 
O'Connor (2016)23 
Population ≥ 65 
years 513 89 Author defined 71 79.78 
O'Connor (2012)22 
Population ≥ 65 
years 372 178 Author defined 43 24.00 
Onder (2010)24 
Population ≥ 65 
years 6419 383 Author defined 221 64.00 
O'Sullivan (2016)25 
Population ≥ 65 
years 376 91 Hartwig Scale 76 83.52 
Tangiisuran 
(2012)34 
Population ≥ 65 
years 560 83 Hallas 60 72.29 
Kaur (2018)20 
All ages author 
supplied 
467 106 Hartwig Scale 70 66.06 
Davies (2009)14 
All ages author 
supplied 
1787 476 Hartwig Scale 385 80.88 
Ganeva (2016)16 
All ages author 
supplied 
97 13 Hartwig Scale 10 76.92 
Ganeva (2013)17 








All ages author 
supplied 
222 17 Author defined 6 54.55 
Hailu19 
All ages author 
supplied 
121 3 Hartwig Scale 3 100 
Bowman (1996)8 
All ages 
(29.39% ≥ 65 
years) 
301 89 Venulet 64 72.00 
Calderon-Ospina 
(2010)9 
All ages  
(48.15% ≥ 65 
years) 
48 13 Author defined 13 100.00 
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(52.74% ≥ 65 
years) 
244 35 




*Reporting ADRs that are moderate, severe, serious or life threatening 
 
Appendix 23. Meta-analysis ADR Reported Severity 
 
Appendix 23. Forest plot of pooled estimate (binomial-normal random effects model) of proportion 
of severe ADRs across eighteen studies.8,9,12-17,19-26,31,34  
This estimate is limited by the high level of heterogeneity and substantial variability across included 
studies (as evidenced by I2 and 2 value). Hence, the estimate should be interpreted with caution as 
rather than considered as a “true” estimate.  
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Appendix 24. Preventability 
ADRs preventability was assessed in 7 studies.9,14,16,19,23,28,34 Preventable in this instance is as defined 
by the various study methodologies. Studies did not report on the details of which ADR 
presentations or ADR-Drug pairs were “preventable”. Four studies14,16,23,28,34 had extractable data 
and used the same tool (Hallas).  
Source Population Tool Details of Preventability 
O’Connor (2016)23 Population ≥ 65 years Hallas 78 patients 89 ADRs 
85 ADRs (95.5%) definitely 
or possibly avoidable  
Tangiisuran (2012)34 Population ≥ 65 years Hallas 74 patients 83 ADR  
“69% of life-threatening or 
serious deemed 
preventable” 
Life-threatening = 3 
Serious = 57 
41 (59%) ADRs preventable  
Davies (2009)14 All ages author supplied Hallas  328 patients 476 ADRs 
262 (55.04%) preventable 
25 definitely 
237 possibly 
214 unavoidable  
Ganeva (2016)16 All ages author supplied Hallas 11 patients ADRs 




Hailu (2020)19 All ages author supplied Not specified  3 patients ADRs 
2 preventable  
Calderon-Ospina 
(2010)9 
All ages  
(48.15% ≥ 65 years) 
Schumock & Thornton 50% (33.1-66.9%) of ADRs 
were considered 
preventable (all ages) 
Giardina28 All ages 
(75.93%≥ 65 years) 
Schumock & Thornton Probably preventable in 
69.4% (all ages) 
unavoidable 24.2% 
6.4% certainly preventable  
Supplemental Materials – In-hospital adverse drug reactions in older adults; prevalence, 
presentation and associated drugs – a systematic review and meta-analysis 
72 
 
Appendix 25. Meta-analysis of pooled estimate of “preventable” ADRs in studies (n=4) 
using Hallas tool 
 
Appendix 25. Forest plot of pooled estimate (binomial-normal random effects model) of proportion 
of preventable ADRs across four studies using comparable reporting. 14,16,23,28,34 
In addition to being a small sample-size in context of overall pooled population, this estimate is 
limited by the high level of heterogeneity and substantial variability across included studies (as 
evidenced by I2 and 2 value). Hence, the estimate should be interpreted with caution as rather than 
considered as a “true” estimate. 
Appendix 26. Reported Polypharmacy 
Details pertaining to medication-burden were reported in 18 studies.7,13,17-25,27-31,34,35 (11 whose 
population was ≥65 years, 6 whose population was all ages author supplied data for cohort of 
interest and 4 studies reported data for all ages). Polypharmacy (i.e. ≥ 5 daily medications at baseline 
reported as a mean/median) was present in 11 studies.7,13,17,21-25,27,30,34,35 
 
Source Population Medication burden Comments/further details 
Corsonello13 Population ≥ 65 years 10.6 ± 5.5 a # drugs per stay (excl. 
PIMs) 
ADR group vs non-ADR 




Population ≥ 65 years 9 IQR 3-16b 81 patients (84%) ≥ 6 drugs 
Lavan30 Population ≥ 65 years 9.9 ± 3.8 a - 
Leach21 Population ≥ 65 years 
 
Mean 6.1 mode 4 Incidence ADRs increased 
with number of drugs 6% 1-
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Population Medication burden Comments/further details 
Liao31 Population ≥ 65 years Medications 
measured by number 
of drug classes during 
whole hospital stay 
ADR 14.98 ± 0.43 a 
Non-ADR 14.95 ± 0.22a 
P = <0.01 
O’Connor (2016)23 Population ≥ 65 years 8 IQR 6-11b 291 (78%) ≥ 5 drugs  
O’Connor (2012)22 Population ≥ 65 years 7 IQR 1-10b 345 (67%) ≥ 6 drugs  
ADR median 10 
Non-ADR median 7 p<0.001 
Onder24 Population ≥ 65 years 3911 (66%) GIFA study 








425 (88%) val. Study ≥ 
5 drugs 
ADR group 3579 (64%) ≥ 5 
drugs 
Non-ADR group 332 (87%) 
≥ 5 drugs 
5-7 drugs OR 1.9 (1.35-
2.68) 
≥8 drugs OR 4.07 (2.93-
5.65) 
 
ADR group 52 (93%) ≥ 5 
drugs 
Non-ADR group 373 (87%) 
≥ 5 drugs 
p=0.001 
O’Sullivan25 Population ≥ 65 years 8 IQR 6-11b 321 (85.4%) ≥ 5 drugs 
control arm 
Tangiisuran (2012)34 Population ≥ 65 years 5 IQR 3-7b  Baseline, total  
ADR 6 IQR 3-8 b 
Non-ADR 5 IQR 3-7 b 
p<0.05  
On ward, total 
ADR 10 (7.75-13)b 
Non-ADR 7 (5-10) b 
P<0.05 
Tangiisuran (2014)35 Population ≥ 65 years Dev. 6 IQR 3-8b 
Val. 5 IQR 4-8b 
Dev. Range 0-18 
 
Ayub7 All ages, author supplied  17.2 ± 2.4a Min 13 Max 20 
Ganeva (2013)17 All ages author supplied 6.1 ± 2.4 a -  
Harugeri29 Population >60 years 
(40% >70 years) 
Overall not described Overall medications higher 
in ADR group median 10 
(range 3-22) non-ADR 
group median 9 (range 1-
21) p<0.001 
Giardina28 All ages 
(75.93% ≥ 65 years) 
Overall 48% ≥ 5 
medications  
- 
Gonzalez-Martin18 All ages 
(52.74% ≥ 65 years) 
Overall not described Number of medications 
administered: A significant 
difference was observed 
between the patients > 65 
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years, in relation to the 
number of medications 
received during 
hospitalization and the 
frequency of ADR (9.0 ± 
2.3a medications vs. 5.5 ± 
2.2 a medications ) (t = 7.6, 
p <0.05).  
Contd.  
Source 
Population Medication burden Comments/further details 
Hailu19 All ages 
(60.5% ≥ 65 years) 
Overall 3.9 ± 2.108 a Overall, 71 (35.5%) had 
polypharmacy (defined ≥5) 
Kaur20 All ages 




Population (>50 years)  
Polypharmacy ≥ 3 drugs 
467 (71%) ≥ 65 years 
a - Mean ± standard deviation; # - number; excl. – excluded; PIMs – potentially inappropriate medications;  b - 
Median IQR; IQR – interquartile range; ADRs – Adverse drug reaction; GIFA – gruppo Italiano di 
farmacovigilanza nell’Anziano; OR – Odds Ratio; Val. – validation; Dev. – development 
 
Appendix 27. Reported multi-morbidity  
Eleven studies examined the degree of co-morbidity as an ADR-associated 
variable.7,13,17,19,22,24,27,30,31,34,35 Baseline multi-morbidity (defined as a mean/median of ≥ 3 chronic 
conditions) was reported in 10 studies.7,13,22,24,27,30,31,34,35  
Source Population Multi-morbidity  Comments/further details 
Corsonello13 Population ≥ 65 years 3.7 ±1.9a Based on CIRS 
ADR vs non ADR CIRS 




Population ≥ 65 years 8 ± 3a Range 1-17 
Lavan30 Population ≥ 65 years 5.4 ± 1.9a 
5 IQR 4-6b  
Range 2-13 
10% ≥ 8 conditions 
Liao31 Population ≥ 65 years 1831 of 2393 (76%) ≥4 
comorbidities 
ADR 4.06 ± 1.48 a 
Non-ADR 3.53 ±1.08 a 
p = <0.001 
O’Connor (2012)22 * Population ≥ 65 years 412 (80%) ≥ 4 
comorbidities 
ADR 115 (85%) ≥ 4 
comorbidities 
Non-ADR 301 (79.6%) ≥ 4 
comorbidities 
p=0.157 






347 (72%) val. ≥ 4 
comorbidities 
ADR group 252 (66%) ≥ 4 
comorbidities 
Non-ADR group 2744 (49%) 
≥ 4 comorbidities 
p=<0.001 
 
ADR group 49 (88%) ≥ 4 
comorbidities 
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Non-ADR group 298 (70%) 




Population Multi-morbidity  Comments/further details 
Tangiisuran (2012)34 Population ≥ 65 years 8 IQR 6-10b ADR 
8 IQR 6-10b Non-ADR 
- 
Tangiisuran (2014)35 Population ≥ 65 years 8 IQR 6-10b Dev. 
Val. Not documented 
- 
Ayub7 All ages author supplied  4.71 ± 1.6a Range 2-7 
ADR 4.8 ± 1.3a 
Non-ADR 3.6 ± 1.7a 
p=0.475 
Ganeva (2013)17 All ages author supplied 2.7 ± 1.8a - 
Hailu19 All ages 
(60.5% ≥ 65 years) 
2.20 ± 1.157 a Adjusted odds ratio (all 
ages) 1.588 (1.03–2.45) p = 
0.04 
a - Mean ± standard deviation; CIRS – cumulative illness rating score; ADRs – Adverse drug reaction; * - 
identified from subsequent publication51;  b - Median IQR; IQR – interquartile range; GIFA – gruppo Italiano di 
farmacovigilanza nell’Anziano; Dev. – development; Val. – validation 
 
Appendix 28. Reported ADR outcomes  
Clinical outcomes following ADRs were infrequently reported, only 9 papers12,14,17,20,22,23,25,31,34 
commented on mortality and/or LOS. Pooled analysis was not feasible. 
Source Population Outcome details  
Conforti12 Population ≥ 65 years ADR LOS 18.7 (95% CI 17.2-20.1)a 
Non-ADR LOS 12.6 (95% CI 11.9-12.3)a 
No comment on statistical significance. 
Corsonello13 Population ≥ 65 years ADRs impact on functional decline  
Increasing # ADRs = loss of ADLs  1 ADR OR 
11.1(4.18-29.5) p=0.001 loss ≥1ADLs 
Increasing severity of ADR = loss of ADLs 
Moderate to severe ADR OR 8.11(2.67-24.6) p=<0.01 
Liao31 Population ≥ 65 years ADR group had increased length of stay (days). 
30.8±30.2 a vs 16.9±14.7 a p = <0.01 
 
ADR group had higher total medical expenses.  
US$ 9531.3±13634.5 a vs 4108.9±5180.1 a p=<0.01 
 
ADR group had higher drug expenses.  
US$ 2276.4±4244.1 a vs 817.0±1806.8 a p=<0.01 
O’Connor (2016)23 Population ≥ 65 years ADR LOS 10 IQR 6-17 b 
Non-ADR LOS 7 IQR 4-14 b 
Death 9 (control arm; unknown if ADR related) 
O’Connor (2012)22 Population ≥ 65 years ADR LOS 12 b 
Non-ADR LOS 7 b 
Death 29 (5.64%) 
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Population Outcome details  
O’Sullivan25 Population ≥ 65 years ADR LOS 11 IQR 7-18 b 
Non-ADR LOS 8 IQR 5-13 b p<0.001 
Death 17 (4.5% control arm; unknown if ADR 
related) 
Tangiisuran (2012)34 Population ≥ 65 years ADR LOS 14 IQR 10-26.5b 
Non-ADR LOS 12 IQR 7-19 b 
Davies14 All ages author supplied ADR LOS 22 IQR 14-37b 
Non-ADR 10 IQR 6-17b  
Death 165 (11 ADR related) 
Ganeva (2013)17 All ages author supplied ADR LOS 9.2 ± 3.4a 
Harurgeri29 Population >60 years 
(40% >70 years) 
Overall ADR group had longer LOS 
ADR LOS median 7 (range 1-43) 
Non-ADR 6 (range 1-20) p=0.02 
Gonzalez-Martin18 All ages 
(52.74% ≥ 65 years) 
Patients> 65 years with ADRs had a longer hospital 
stay than those without ADRs (9.57 ± 7.55 a days vs. 
5.21 ± 3.21 a days) p <0.05 
Kaur20 All ages 
(70.97% ≥ 65 years) 
ADR LOS +2 days 
Death 3 ≥ 65 (unknown if ADR related) 
LOS – length of stay in days; CI – Confidence Interval; a - Mean ± standard deviation; ADL – Activities of Daily 
Living; OR – Odds Ratio;  b - Median IQR; IQR – interquartile range; ADRs – Adverse drug reaction; GIFA – 
gruppo Italiano di farmacovigilanza nell’Anziano; Dev. – development; Val. – validation 
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